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 Physical activity is an accepted intervention for the prevention of diabetes mellitus (DM) and 
insulin resistance (IR) in the general population. Few studies in HIV-infected persons assessed 
the role of physical function or physical activity as a contributing factor to glucose disorders.  
The relationship between self-reported and performance-based measures of physical function in 
HIV-infected individuals has not been assessed.  This dissertation examined associations 
between self-reported and performance-based measures of physical function, DM, and IR in 
HIV-uninfected and HIV-infected men. 
 Data from 658 men from the Pitt Men’s Study were analyzed to assess the contribution of 
self-reported physical function to prevalent DM and IR.  Physical function score (AOR 1.5 per 
25 unit decrease, p=0.02) was significantly associated with diabetes, but not IR, after adjustment 
for covariates.  
Data from 1790 men from the Multicenter AIDS Cohort Study (MACS) were used to 
assess physical function as a risk factor for incident DM and IR.  Cumulative DM incidence was 
highest among HIV-uninfected and HIV-infected men with low physical function.  Low physical 
function was a risk factor for incident DM in HIV-uninfected men using more stringent (HR 
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1.31; 95% CI 1.02-1.66) and less stringent (HR 1.29; 95% CI 1.11-1.50) diabetes definitions 
adjusting for BMI, family history of diabetes and race.  Among HIV-infected men, physical 
function was a risk factor for incident DM using the less stringent diabetes definition.   
 To assess the relationship between self-reported and performance-based measures of 
physical function, DM and IR, a cross-sectional study of 2079 men from the MACS was 
conducted.  Self-reported physical function and performance-based measures correlated weakly. 
(HIV-uninfected: ρ=0.12-0.23, p<0.01; HIV-infected ρ=0.16-0.24, p<0.01).  Self-reported 
physical function had a stronger association with DM and IR than performance-based measures 
in HIV-uninfected but not HIV-infected men. 
There are important public health implications of this dissertation.  Low physical function 
is a risk factor for DM in two cohorts of HIV uninfected and HIV-infected men; therefore 
interventions to increase physical function may decrease DM risk while simultaneously reducing 
the risk of further disability and chronic sequelae among HIV-infected individuals already 
diagnosed with diabetes.   This is essential given the national burden of HIV infection and DM.  
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1.0  INTRODUCTION 
1.1 SPECIFIC AIMS 
Physical activity is an accepted intervention for the prevention and management of diabetes 
mellitus (DM) and insulin resistance (IR) in the general population1-9.  However, its role in the 
prevention of DM has not been addressed in most studies of HIV-infected populations10-14.  
 Numerous studies in HIV-uninfected populations have established that physical activity 
levels are correlated with physical function 15-20.  Among HIV-infected persons, resistance 
training has been shown to improve self-reported physical function in patients with HIV 
wasting21.   Therefore, physical function is likely to reflect physical activity.  To date, no studies 
have assessed the association between self-reported and performance-based measures of physical 
function, diabetes mellitus, and insulin resistance in HIV-infected men.  The goal of the 
proposed research is assess the association of physical function, a correlate of physical activity, 
with diabetes mellitus and insulin resistance and, further, to compare self-reported physical 
function with performance-based measures of physical function in HIV-infected and HIV-
uninfected men. 
The following research aims and hypotheses will be used to achieve this goal: 
1. To investigate the association between self-reported low physical function and 
prevalent and incident diabetes mellitus among HIV-infected and HIV-uninfected 
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men.  We hypothesize that low physical function will be independently associated 
with both prevalent and incident diabetes mellitus in HIV-infected and HIV-
uninfected men. 
2. To investigate the association between low physical function and prevalent and 
incident insulin resistance among HIV-infected and HIV-uninfected men.  We 
hypothesize that low physical function will be independently associated with both 
prevalent and incident insulin resistance in HIV-infected and HIV-uninfected 
men. 
3. To compare incidence rates of diabetes in HIV-infected and HIV-uninfected men 
with low physical function to HIV-infected and HIV-uninfected men with high 
physical function.  We hypothesize that HIV-infected and HIV-uninfected men 
with low physical function will have higher cumulative incidences of diabetes 
than HIV-infected and HIV-uninfected men with high physical function. 
4. To assess the relationship between self-reported and performance-based 
measures of physical function in HIV-infected and HIV-uninfected men.  We 
hypothesize that performance-based measures of physical function will be 
significantly correlated with self-report physical function in both HIV-infected 
and HIV-uninfected men. 
3 
5. To determine whether self-report or performance-based measures of physical 
function are more strongly associated with prevalent diabetes mellitus and insulin 
resistance in HIV-infected and HIV-uninfected men.  We hypothesize that the 
performance-based measures of physical function will have a stronger 




1.2.1  Introduction 
 The introduction of highly active antiretroviral therapy (HAART) dramatically changed the 
course of HIV infection.  Individuals living with HIV infection are now faced with co-
morbidities that are common in the general population.  Type 2 diabetes mellitus (DM) and 
insulin resistance (IR) are two such conditions.  To date, the etiology of DM and IR in HIV-
infection remains unclear.  Traditional risk factors such as advancing age and higher body mass 
index (BMI) have consistently been reported and HIV-specific risk factors such as HAART use 
are thought to play a role.  Physical activity is a well accepted intervention for the prevention of 
DM in the general population, yet its role has been overlooked in the majority of studies of DM 
in HIV-infected persons.  The purpose of this literature review is to evaluate what is currently 
known about glucose disorders in the HIV-infected population as well as to underscore the 
paucity of physical activity literature in this specific population.  In addition, the correlation 
between physical activity and physical function will be addressed. 
1.2.2 Glucose disorders 
1.2.2.1 Diabetes 
Diabetes mellitus is a disease in which the body does not either produce or properly use insulin22, 
23.  Insulin helps to maintain normal blood glucose levels in the body by improving the glucose 
uptake from the blood across cell membranes using the glucose transporter GLUT424. Diabetes is 
a complex chronic disorder of carbohydrate, fat, and protein metabolism that is typically the 
result of a relative or a complete lack of insulin secretion by the beta cells of the pancreas or due 
to defects of the insulin receptors25. In diabetes, the pancreas does not make enough insulin 
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(Type 1) or can’t respond normally to the insulin that is made (Type 2).  This leads to an increase 
in blood glucose levels which can cause acute complications (diabetic ketoacidosis) as well as 
long term complications (cardiovascular disease, nephropathy, retinopathy, neuropathy) typically 
requiring continued medical care and patient self management22, 25. Currently, the American 
Diabetes Association (ADA) recognizes 4 classes of diabetes: 1) type 1 diabetes resulting from 
Beta cell destruction typically resulting in absolute insulin deficiency; 2) type 2 diabetes 
typically resulting from insulin resistance combined with relative insulin deficiency; 3) other 
specific types of diabetes due to causes such as genetic defects in Beta cell function, genetic 
defects in insulin action, diseases of the exocrine pancreas and drug or chemical induced; and 4) 
gestational diabetes mellitus which is diagnosed during pregnancy22.   
 Type 2 diabetes occurs most frequently in older adults and is often not diagnosed until 
symptoms occur.  It is estimated that one-third of all individuals with diabetes are undiagnosed22. 
Over the past 50 years, the prevalence and incidence of obesity, insulin resistance and type 2 DM 
have been increasing throughout the world at alarming rates26.  Individuals with Type 2 DM 
comprise 90-95% of all cases of DM worldwide24. It is estimated that the number of type 2 
diabetes cases will double from 171 million in 2000 to 366 million in 2030 with incidence rates 
increasing faster in developing countries24, 27.  The worldwide prevalence in adults was 4.0% in 
1995 and may rise to as high as 5.4% by 202528.  In the United States, a six fold increase in the 
prevalence of type 2 DM was reported between 1958 and 1993 with current estimates suggesting 
that 6-8% of adults have diabetes4, 5, 26, 29; however the true prevalence may be closer to 10% 
after considering undiagnosed cases4, 5, 29. This has lead to an estimated national burden in excess 
of $174 billion ($116 billion in excess medical expenditures and $58 billion in decreased 
national productivity from premature disability, premature death, missed work days, restricted 
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activity, and sick leave) 7, 24. While the specific etiologies of type 2 DM remain unknown, certain 
risk factors are well documented24.  These include family history of DM, age, race/ethnicity, 
obesity, and physical inactivity.  
The risk of developing diabetes for an individual with a positive family history varies 
depending upon the family member’s age, the age at diagnosis and the type of diabetes mellitus.  
The risk of a child developing type 2 diabetes is approximately 14% if the parent with DM was 
diagnosed before age 50 and 8% if diagnosed after age 50.  The risk increases to 50% if both 
parents have type 2 DM24.  Older age can also lead to an increased risk of developing type 2 DM, 
with the greatest risk occurring in persons aged 45 years and older24.  This is likely due to a 
combination of loss of muscle mass with subsequent increases in body fat (especially in the 
abdomen) as well as defects in fatty acid oxidation in muscle with aging (which enhances insulin 
resistance) 24, 30.  In addition, racial/ethnic minorities including African, Hispanic, Indian, Asian 
Americans, and Pacific Islanders have a greater risk of developing type 2 DM.  This is likely due 
to a combination of environmental, genetic, and metabolic differences24. Individuals with a body 
mass index (BMI) of > 25 kg/m2 (normal BMI = 18-25 kg/m2) are considered to be at an 
increased risk for type 2 DM8, 31.  Large waist circumference is also associated with an increased 
risk of type 2 DM, likely due to its use as surrogate for abdominal fat distribution24.  
Physical inactivity can lead to the development of obesity and modifies muscle insulin 
sensitivity, both of which increase risk of type 2 DM development2, 24.  Other factors such as 
dyslipidemia, hypertension, prior gestational diabetes, polycystic ovary syndrome (PCOS), 
inflammation, and prothrombotic factors are also thought to increase the risk of developing DM.   
Early diagnosis is critical for diabetes management.  According to ADA criteria, there are 
3 ways to diagnose diabetes, each of which must be confirmed on a subsequent day22: 1) 
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symptoms of diabetes such as excessive urination, excessive thirst, unexplained weight loss and 
a casual plasma glucose of  > 200 mg/dL (casual is defined as “any time of day without regard to 
time since last meal”) or 2) fasting plasma glucose (FPG)  > 126 mg/dl where fasting is defined 
as no caloric intake for at least 8 hours or 3) 2-h plasma glucose > 200 mg/dl during a 75-g oral 
glucose tolerance test (OGTT) as described by the World Health Organization.  Hyperglycemia 
that does not meet the aforementioned criteria is classified as either impaired fasting glucose or 
impaired glucose tolerance depending upon the diagnostic test used.  IFG is defined as an FPG of 
100 mg/dl to 125 mg/dl while IGT is defined as a 2 hour OGTT of 140 mg/dl to 199 mg/dl. 
People with IFG and IGT, who are at risk for DM, have recently been officially designated as 
having “pre-diabetes22.” Normal glucose tolerance is defined as an FPG < 100 mg/dl. Impaired 
glucose tolerance and impaired fasting glucose can increase the risk of DM development.  
Individuals diagnosed with IFG or IGT have a 40% risk of developing type 2 DM over the next 5 
years 24. 
1.2.2.2  Insulin Resistance 
In the U.S. alone, it is estimated that 70-80 million people have insulin resistance syndrome3.  
Insulin resistance is defined as the diminished ability of cells to respond to the action of insulin 
in transporting glucose from the blood stream into the muscle or other tissues24.  The pancreas 
overproduces insulin in response to this resistance.  If the body can produce enough insulin to 
overcome this resistance, blood glucose levels remain normal.  The overproduction of insulin 
(hyperinsulinemia) can lead to an excess of glucose and insulin in the bloodstream as cells 
become resistant to insulin.  Insulin resistance, in turn, may ultimately progress to DM.  IR is 
likely caused by a combination of genetic and environmental factors (such as physical inactivity 
and diet) 6, 24.  IR can include both elevated blood glucose levels and elevated levels of 
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circulating insulin24.  Several mechanisms are thought to lead to IR including reduced binding of 
insulin to the insulin receptor, changes in intracellular signaling pathways, and defective cellular 
uptake of glucose32.  IR, in combination with insulin deficiency, likely plays a key role in the 
pathophysiology of type 2 DM.  Defects in insulin secretion, abnormalities in glucose uptake and 
insulin resistance are uniform findings in type 2 DM3.  The body’s ability to maintain glucose 
homeostasis depends upon the normal insulin secretory response by the pancreatic beta cells as 
well as normal tissue sensitivity3, 6, 24.  Risk factors for IR are similar to those of DM and include 
obesity, physical inactivity, family history of DM, PCOS, hypertension, hyperlipidemia, and an 
increased waist circumference. 
The current “gold standard” for measuring IR is the hyperinsulinemic euglycemic 
clamp33; however the technique is complicated to administer34. Alternatives such as the 
Quantitative Insulin Sensitivity Index Check (QUICKI) and the homeostasis model assessment 
(HOMA) utilize fasting insulin and glucose levels to calculate IR and were developed to offset 
the complicated nature of the clamp technique.  Both the HOMA (r = -0.820, P < 0.0001)35 and 
the QUICKI (r=0.77, P< 0.0001)36 have been found to correlate well with clamp technique and 
are acceptable for use as a measures of insulin sensitivity and insulin resistance in studies in 
which only a fasting blood sample is available34-38.  
1.2.3  Diabetes and physical activity in HIV-uninfected populations 
1.2.3.1  Physical activity and exercise 
According to the 1996 “Physical Activity and Health” Surgeon General report, physical activity 
(PA)  is defined as bodily movement produced by the contraction of skeletal muscle that requires 
energy expenditure in excess of resting energy expenditure39.  Exercise is a subset of PA that 
9 
consists of planned, structured, and repetitive bodily movements that are performed to either 
improve or maintain one or more components of physical fitness including cardiorespiratory 
fitness, muscular fitness, and flexibility.  While exercise is a type of physical activity, it is 
important to note that not all physical activity is considered exercise16.  An individual may be 
physically active during the day, walking at an occupation, doing housework, etc without 
actually doing structured exercise.  Despite these differences, the terms are often used 
interchangeably. 
 The Surgeon General’s Report recommends 30 minutes of moderate intensity physical 
activity, similar in intensity to brisk walking, on most days of the week, although it is not 
necessary to complete all 30 minutes in one continuous session.  Short bouts of 10 minutes or 
longer completed during a single day are acceptable.  However, 1998 data from the Behavioral 
Risk Factor Surveillance System suggest that a mere 25.4% of individuals participate in the 
recommended level of physical activity while 45.9% and 28.7% report insufficient activity or no 
activity respectively40.  Findings from the Third National Health and Nutrition Examination 
Survey (NHANES III) indicate that 31% of individuals with type 2 DM reported that they do not 
partake in physical activity while an additional 38% reported that they participated in less than 
the recommended levels of physical activity41.  
1.2.3.2  Prevention of diabetes 
Throughout the years, the role of physical activity in preventing type 2 DM in HIV-uninfected 
individuals has become well established.  Four major clinical trials (three of which were 
randomized) and numerous large cohort studies provide strong evidence to suggest that physical 
activity can reduce the incidence of DM42-50.  The Swedish Malmo Feasibility study was the 
earliest clinical trial aimed at preventing diabetes42.  This six year non-randomized trial enrolled 
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161 men with impaired glucose tolerance (IGT) in a diet-plus-physical activity intervention and 
compared these men to 56 men with IGT who declined the same intervention.  After 6 years, the 
cumulative incidence of type 2 DM was 11% in the diet-plus-PA group compared with 21% in 
the control group (relative risk (RR) 0.37, 95% CI 0.20-0.68)42.  In addition, after 12 years of 
follow-up, the mortality among men with IGT in the intervention group was 6.5 per 1,000 person 
years versus 14.0 per 1000 person-years in the control group43.  Despite these encouraging 
results, the study had an important limitation.  As previously mentioned, this trial was non-
randomized therefore baseline differences between groups (the 2 arms differed by medical 
conditions) affected the study’s internal validity.  
The first randomized trial, the Da Qing IGT and Diabetes Study, addressed life style 
interventions with the goal of preventing type 2 DM48, 49.  This study randomized, by clinic site, 
577 Chinese men and women aged 25 years and older with IGT to one of four interventions: 
diet-only, exercise-only, diet-plus-exercise, and a control group.  Subjects were followed for six 
years and the cumulative incidence of DM was calculated.    The cumulative incidence of type 2 
DM was highest in the control group (68%), followed by the diet group (44%), the exercise 
group (41%) and the diet plus exercise group (46%) respectively.  Each intervention group 
differed significantly from the control group (p<0.05).  In a proportional hazards model 
comparing the intervention groups to the control group after adjustment for body mass index and 
fasting glucose, there was an overall lower incidence of DM by 31% in the diet-only group 
(p<0.03); 46% in the exercise-only group (p<0.0005) and 42% in the diet-plus-exercise group 
(p<0.005)48.  This study provides evidence to suggest that both diet and exercise can be 
important interventions in preventing DM.  This study did however have two major limitations: 
1) randomization occurred at the clinic level rather than at the participant level and 2) the 
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baseline exercise units for the two PA groups were significantly higher than the control or diet-
only group.  Generalizability of results is also limited as this study restricted participating clinics 
to a single city in China (Da Qing).  Therefore results may not extend to other ethnic groups 
especially given the leanness of the Da Qing cohort (mean BMI ~ 23 kg/m2).  
Results from subsequent clinical trials completed in Finland and the United States 
produced similar results but differed from the Da Qing study by randomizing individual 
participants rather than clinics.  In the Finnish Diabetes Prevention Project 522 overweight 
participants with IGT ranging in age from 40-65 years were randomized to a lifestyle 
intervention (with both a dietary and a PA component) or a control group44, 45, 47.  The cumulative 
incidence of DM after 4 years was 11% in the intervention group compared with 23% in the 
control group.  In Cox regression models, the cumulative incidence in the intervention group was 
58% lower (hazard ratio (HR) 0.4; p<0.01) than in the control group.  The incidence of DM was 
reduced by 63% in men (p=0.01) and by 54% in women (p=0.008).  A post-intervention follow-
up study by the same group produced similar results.  The incidence rates were 4.3 per 100 
person years in the intervention group and 7.4 per 100 years in the control group (p=0.0001) with 
a corresponding HR of 0.57.  The 6-year cumulative incidence for DM was 23% in the 
intervention group and 38% in the control group46.   
The Diabetes Prevention Program (DPP) was a large, randomized clinical trial conducted 
in the U.S. which included 3234 overweight men and women 25 years and older with impaired 
glucose tolerance50.  The study’s objective was to determine whether a lifestyle intervention or 
treatment with metformin would prevent or delay the onset of type 2 DM.  Participants were 
randomized to one of three interventions: standard lifestyle recommendations plus metformin, 
standard lifestyle recommendations plus placebo, or an intensive lifestyle modification program 
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and were followed for a mean of 3.2 years.  The crude incidence of diabetes was 11.0, 7.8, and 
4.0 cases per 100 person years in the placebo, metformin, and lifestyle intervention groups 
respectively after a mean of 2.8 years of follow-up.  The risk reduction was 58% in the lifestyle 
group and 31% in the metformin group compared to the placebo group.  In addition, the 
incidence of diabetes was 39% lower in the lifestyle group than the metformin group.  The 
estimated cumulative incidence of DM at three years was 28.9% in the placebo group, 21.7% in 
the metformin group and 14.4% in the lifestyle intervention group.  These results were similar in 
both men and women as well as in all racial and ethnic groups50.  
In addition to these 4 well known clinical trials, a number of large cohort studies51-60 and 
smaller clinical trials61, 62 also found that higher levels of exercise and/or cardiorespiratory fitness 
were associated with a decreased risk of developing type 2 DM.  The independent effect of 
exercise remained, when accounting for known diabetes risk factors including hypertension, 
familial history of DM, and obesity.   
Despite the consistent findings from these clinical trials, it is important to note that a few 
questions regarding physical activity and diabetes are not yet answered63.  The aforementioned 
clinical trials provide strong evidence for the promotion of lifestyle interventions in the 
prevention of type 2 DM; however in 3 of the 4 trials the independent effect of activity alone was 
not tested.  All of the trials, except the Da Qing Study, used a combined lifestyle intervention 
including physical activity, diet, and weight loss.  Therefore, in order to truly understand the role 
that PA plays in preventing type 2 DM, the physiological effect of this relationship needs to be 
better defined. 
Given the results of the aforementioned studies, the American Diabetes Association 
(ADA) maintains that “the importance of promoting physical activity as a vital component of the 
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prevention as well as management of type 2 diabetes must be viewed as a high priority64.”  In 
addition, the ADA suggests that the exercise benefits of improved metabolic abnormalities in 
type 2 DM are greatest when exercise is introduced early in the progression of the disease64. 
1.2.3.3  Metabolic effects of physical activity in diabetes management 
Although physical activity has been used for decades as an important facet of diabetes 
management, it has only been in the past few years that good quality evidence strengthened the 
importance of its use65.  Numerous cross-sectional and cohort studies provide evidence that 
physical inactivity is associated with impaired glucose tolerance66-71.  Physical activity can lower 
blood glucose by its synergistic action with insulin in tissues that are insulin-sensitive72.  The 
specific metabolic effects of physical activity on type 2 diabetes and insulin resistance follow. 
 Boulé et al conducted a meta-analysis of controlled clinic trials (through December 2000) 
on the effect of physical activity interventions (> 8 weeks duration) on glycemic control in type 2 
diabetics using glycosylated hemoglobin (HbA1c)73.  In pooled post intervention results, HbA1c 
was significantly lower in the intervention groups as compared to the control groups (7.65% 
versus 8.31%, weighted mean difference -0.66%; p<0.001).  Boulé et all suggested that a 
reduction in HbA1c by 0.66% was significant enough to reduce the risk of diabetes complications 
and was similar in effect to differences between conventional and intensive glucose-lowering 
therapy in the United Kingdom Prospective Diabetes Study74, 75.  In addition, the data from the 
meta-analysis was taken from a number of different ethnic populations, ages, dietary 
interventions and medication interventions, and can thus be generalized to middle aged 
individuals with type 2 DM.  Post intervention body weights did not significantly differ between 
the intervention and control groups (weighted mean difference 0.06, p=0.60).  Meta-regression 
analysis indicated that the HbA1c difference were independent of body weight (weight loss), 
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exercise intensity, or exercise volume.  This finding suggests that even without weight loss, 
exercise can beneficially impact glycemic control.  Exercise affects a number of mechanisms, 
not necessarily involved with weight loss, that decrease hepatic and muscle insulin resistance 
while increasing glucose disposal.  These mechanisms include increased post receptor insulin 
signaling, increased glucose transporter and messenger RNA, increased glycogen synthase and 
hexokinase activity, decreased release and clearance of free fatty acids, increased muscle glucose 
delivery (due to an increased muscle capillary density), and changes in muscle composition 
which help to increase glucose disposal76-83.  
In their randomized trial of 251 adults ages 39 to 70 years with type 2 DM, Sigal et al 
also reported improvements in HbA1c with aerobic and resistance training84.  The absolute 
change in HbA1c value in the aerobic training group was -0.51 percentage point compared to the 
control group (95% CI, -0.87 to -0.14).  Similarly, a change of -0.38 was observed in the 
resistance training group compared with the controls (95% CI -0.72 to -0.22).  The control group 
had an increase in HbA1c of 0.07 percentage point whereas the aerobic group and resistance 
group had decreases of 0.43 and 0.30 percentage points respectively. 
During physical activity, a 20-fold increase in whole-body oxygen consumption can 
occur in the working muscles.  Skeletal muscle will use its own stores of glycogen, triglycerides, 
and free fatty acids from the breakdown of adipose tissue triglycerides and glucose released from 
the liver to meet the body’s energy needs during exercise64.  
Skeletal muscle IR is the characteristic feature of patients with type 2 DM26.  Although 
the primary cause of whole-body insulin resistance remains unclear, recent studies have 
improved our understanding of the molecular basis that leads to the beneficial role of exercise in 
stimulating the entry of glucose into insulin-sensitive tissues.  These mechanisms include defects 
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in early and intermediate insulin signal transduction in skeletal muscle, gene expression, enzyme 
regulation, and lipid dynamics breakdown26.  Insulin-mediated glucose uptake takes place mostly 
in skeletal muscle and is directly related to the amount of muscle mass while inversely associated 
with fat mass.   
It has become well accepted that regular exercise is an effective therapy to improve 
insulin action in the skeletal muscle of insulin resistant individuals3, 72, 85, 86.  Studies suggest that 
exercise increases both peripheral and visceral insulin sensitivity for 12 to 24 hours post exercise 
among individuals with type 2 DM72, 87-89.  Exercise training studies have also established that 
PA can improve insulin sensitivity independent of its effect on weight loss and fat  
distribution81, 90. 
1.2.4 HIV Epidemiology 
More than twenty-five years have passed since the first cases of the human immunodeficiency 
virus (HIV) emerged yet today the disease remains one of considerable public health 
significance.  According to 2006 UNAIDS data, an estimated 38.6 million individuals live with 
HIV worldwide; 1.1 million of these reside within in the United States91, 92.   The majority of 
individuals living with HIV in the US at the end of 2006 were nonwhite (65.4%) and almost half 
were men who have sex with men (MSM) (48.1%)92.  Of the prevalent cases 74.8% were males 
and 70% of persons living with HIV in the US were between the ages of 25-49.  In August 2008 
the Centers for Disease Control and Prevention (CDC) estimated that approximately 56,300 
people were newly infected with HIV in the United States in 2006 (95% CI: 48,200–64,500)93.   
This is higher than the previous estimate of 40,000.  The new estimate also confirmed that gay 
and bisexual men of all races, African Americans, and Hispanics/Latinos were most affected94.   
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HIV infects CD4 cells by integrating into host DNA.  The virus converts its RNA into 
DNA through the use of a reverse transcriptase enzyme95.  If left untreated HIV infection results 
in a chronic, progressive, and eventually fatal disease characterized by depletion of CD4 
lymphocytes96.  Although HIV and the acquired immunodeficiency syndrome (AIDS) claimed 
545,805 lives in the United States since 1981, the effective use of highly active antiretroviral 
therapy (HAART) throughout the past decade significantly reduced morbidity and mortality 
among those affected with HIV97-99.  
Currently, there are 3 main classes of antiretroviral agents (ARV) in use, the reverse 
transcriptase inhibitors (RTI) [nucleosides (NRTI); non-nucleosides (NNRTI) and nucleotides], 
protease inhibitors (PI), and entry inhibitors100. NRTIs were the first type of drug available to 
treat HIV infection95. They contain faulty versions of the nucleotides used by reverse 
transcriptase to convert RNA into DNA.  Due to the faulty nucleotides, new DNA cannot be 
correctly built and HIV’s genetic material is not incorporated into the cell. Thus replication of 
new virus is prevented. NNRTIs attach directly to the reverse transcriptase enzyme, change its 
shape, and prevent the enzyme from converting RNA into DNA.  Protease inhibitors block the 
ability of the protease enzymes to cut the long strands of amino acids into working proteins for 
HIV95. Therefore, the virus is unable to make copies to infect new cells.  When used in 
combination with RTIs, PIs are the most effective HIV treatment to date95. Entry inhibitors are 
the newest antiviral drugs available to treat HIV infection and work by blocking the attachment 
of HIV to the CD4 T receptor or the CCR5/CXCR4 co-receptors101. 
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1.2.5 Glucose disorders in HIV-infected populations 
The wide spread usage of highly active antiretroviral therapy (HAART) presented unforeseen 
clinical challenges within the dynamic HIV epidemic99. As the paradigm of HIV treatment 
shifted from palliative care to chronic disease management, unexpected metabolic complications 
surfaced102, 103.  Syndromes such as lipoatrophy, visceral fat redistribution and accumulation, 
hyperlipidemia, diabetes mellitus, impaired glucose tolerance, and insulin resistance began to 
occur in both individuals receiving HAART102-106 as well as in HIV-infected patients not using 
ARV agents100. Patients with chronic HIV disease can have an abnormal metabolic profile 
including elevated lipids and insulin resistance.  A full understanding of these complications 
remains elusive, but may involve a combination of antiretroviral therapy and duration of HIV 
infection (likely due to the pro-inflammatory effects of HIV itself103) as well as traditional risk 
factors such as lifestyle, body mass index (BMI)11, 107-110, age, sex, and genetic predisposition111, 
112.  Adiponectin and a high level of free fatty acids have also been implicated with IR among 
individuals with HIV infection.  Similarly, increased fatty acids in HIV patients with fat 
redistribution correlate with IR113, 114. 
1.2.5.1 Diabetes Mellitus 
Prior to HAART introduction, cases of DM and IR rarely occurred in HIV-infected 
individuals115.  Beginning as early as 1998, cross sectional and cohort studies reported an 
increase in glucose disorders among HIV-infected individuals14, 103, 108, 109, 114, 116-120. Prevalence 
estimates of DM among HIV-infected persons have been found to vary greatly and range from 
1% to 16%107-109, 118, 119, 121.  This range likely occurs for a number of reasons, including differing 
study designs and populations as well as the specificity and sensitivity of the diabetes definition 
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used. In one of the first studies, Carr et al reported a 7% DM prevalence among HIV-infected 
participants receiving protease inhibitors116.  However, it is important to note that this study 
lacked an HIV-uninfected control group, had a small size and did not confirm glucose levels by 
subsequent testing.  The majority of studies have documented prevalence rates between 6-
10%,118, 120, 122, 123 however a larger, prospective cohort study in 1278 HIV-uninfected and HIV-
infected men by Brown et al found that prevalent DM was more common in HIV-infected men 
receiving HAART compared to HIV-uninfected men (14% versus 5%)121.  HIV-infected men not 
on HAART were also found to have an increased risk of prevalent DM (PR 2.21; 95% CI 1.12-
4.38) compared to HIV-uninfected men.  However, it is important to note that FG levels were not 
confirmed by a subsequent test, which may have affected prevalence estimates.  Regardless, the 
DM prevalence differences in HIV-infected versus HIV-uninfected participants deserve 
attention.    
Extremes in prevalence estimates are noted.  Brar et al, used a cohort of ART naïve 
participants which may account for their lower prevalence estimates (3.3%) given results from 
studies which suggest that ARVs may play a role in diabetes development107.  They excluded 
participants over the age of 59 years (mean age 38 years) which may partially explain their lower 
estimates107. In addition, their DM definition was based on historic self-report rather than on 
glucose testing. In contrast, Howard et al reported much higher DM prevalence in their cross-
sectional studies of HIV-infected and HIV-uninfected men and women108, 109. The first of these 
studies assessed the associations of HIV, HAART, and other factors with prevalent diabetes in a 
cohort of 288 HIV-uninfected and 332 HIV-infected middle-aged (ages 35-71) women108.  Of 
these women, over 80% were black or Hispanic, 74% were overweight and 75% were not 
physically active.  Diabetes was defined by self-report of a DM diagnosis.  Of the entire cohort, 
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13% reported being told by a health care provider that they had DM and no differences were 
noted by HIV status (12% for HIV-infected and 13% for HIV-uninfected, p = 0.75) or by PI use 
(15% for PI experienced versus 8% for PI-naïve, p=0.06).  A similar study by the same authors 
was conducted in a cohort of 643 HIV-uninfected and HIV-infected men > 49 years.  Of these 
men, over 75% were black or Hispanic, 58% were overweight and 70% were not physically 
active109.  The definition for DM was analogous to their study in women.  Of the entire cohort, 
18% reported being told by a health care provider that they had DM and no differences were 
noted by HIV status (16% for HIV-infected and 20% for HIV-uninfected, p = 0.25) or by PI use 
(18% for PI experienced versus 12% for PI-naïve, p=0.13).  The high prevalence rates in these 
two studies can likely be attributed to the high risk profiles in the study populations.  The 
prevalence of DM in HIV-uninfected subjects (20% for men and 13% for women) was much 
higher than the prevalence in the general population (6-8%)4, 5, 26, 29, 103.  A second study in 
women with similar demographics to the Howard study reported a 10.2% prevalence in HIV-
uninfected women, 8.1% in HAART naïve women, and 4.2% of women on HAART (although 
these differences were not significant)120.  These somewhat surprising results may be due to BMI 
and minority differences between the groups. 
A number of studies have also assessed the incidence of DM in HIV-infected 
populations.  Brown et al121 (n=680 for incidence analysis) reported a 4-fold increase the 
incidence rate of DM in HIV-infected men on HAART compared to HIV-uninfected men (47 per 
1000 person-years [PY] versus 14 per 1000 PY; age and BMI adjusted RR 4.11, 95% CI 1.85-
9.16); however no differences in incidence rates were observed between HIV-infected men not 
using HAART (17 per 1000 PY) and HIV-uninfected men (demographics similar for men on 
HAART and men not on HAART).  Because fasting glucose levels were not confirmed, it is 
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possible that the observed incidence rate in this study is overestimated.  In addition, other factors 
such as physical activity and family history of DM were not assessed and may confound RR 
results.  Ledergerber et al14, in their cohort of 6513 HIV-infected participants from the Swiss 
HIV Cohort Study, reported a much lower incidence of DM (4.42 cases per 1000 person-years, 
95% CI 3.7-5.3) while De Wit et al reported a similar low incidence of new onset DM (5.72 per 
1000 person years, 95% CI 5.31-6.13) in a cohort of 32,437 HIV-infected men and women in 
Europe, the US, Argentina, and Australia.  Explanations for these discrepancies include a lower 
population background DM incidence in Europe compared with the US124, differing study 
demographics (lower mean age and BMI compared with the Brown study) and a confirmatory 
fasting glucose.  However, neither of these studies had an HIV-uninfected control group.   
Results from a multicenter (6 inner city US sites) prospective cohort study of 1435 HIV-
infected and 350 HIV-uninfected women reported an incidence of 14 cases per 1000 person-
years in HIV-uninfected women, 12 per 1000 person-years, 12 per 1000 person-years and 28 per 
1000 person-years in the NRTI, no HAART, and PI groups respectively13.  However, DM cases 
were based on self-report so misclassification was possible.  Tien at el reported incidence rate 
results from the same cohort using fasting glucose levels or initiation of diabetes medications125. 
They reported a DM incidence rate of 19.6 per 1000 person-years in HIV-uninfected women, 
15.3 per 1000 person-years in HIV-infected women not on HAART, 25 per 1000 person-years in 
HIV-infected women on HAART in combination with a PI and 28.9 per 1000 person-years in 
women on non-PI HAART; however none of the relative hazards significantly differed from one 
another.  Therefore, chance cannot be ruled out.  Regardless, these studies are important because 
they provided some insight into the incidence of DM in women, a less studied HIV-infected 
population. 
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This current literature has several limitations including differing DM definitions (making 
prevalence and incidence comparisons difficult), sample size differences and few studies in HIV-
infected women and populations at lower risk for DM.  In addition, it is important to note that the 
differences in DM and IR prevalence and incidence in the post-HAART era compared with the 
pre-HAART era could also be attributed to longer life expectancies (and thus more time to 
develop DM), increased testing and screening, and the 1997 change in diagnostic criteria which 
implemented a lower cutoff for DM (126 mg/dL)126. 
1.2.5.2 Insulin resistance 
Walli et al32, 127 and Carr et al103, 116 were among the first to document the development of insulin 
resistance in HIV-infected individuals in epidemiological studies.  Walli et al32 reported a 61% 
prevalence of IR among patients treated with protease inhibitors as well as significantly lower 
insulin sensitivity (75 µmol/l/min ) compared with therapy naive patients (156 
µmol/l/min, p<0.001).  Cross-sectional studies by Carr found that men on PI therapy had 
significantly higher insulin levels than both HIV-infected men not on PIs and HIV-uninfected 
men (9.1 versus 7.2 versus 5.1 mlU/l respectively) and reported a 16% prevalence of impaired 
glucose tolerance among the men on protease inhibitors103, 116.  Conversely, Danoff et al, did not 
find significant differences in the HOMA score between 88 HIV-uninfected and 179 HIV-
infected women (p=0.4) or by HIV-treatment group120.  However, sample sizes were small in 
these studies and power may have been limited.  Howard et al, did not find any difference in the 
prevalence of impaired glucose tolerance according to PI or HAART use in their cross-sectional 
studies of HIV-uninfected and HIV-infected men109.  In addition, prevalence of IGT did not vary 
by HIV serostatus in men.  Conversely, women receiving non-PI HAART were more likely to 
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have IGT when compared with HIV-uninfected women (25% versus 9%, P=0.02) 108.  Due to the 
cross-sectional design of these initial studies, a temporal relationship between PI use and IR 
could not be determined.  In addition, subjects in these studies were not randomized to treatment 
group; therefore it is possible that other factors (such as PA and other unmeasured variables) 
confounded this relationship.  In a case-control study, Hadigan et al matched 213 healthy HIV-
uninfected control subjects (from the Framingham Offspring Study) to  71 HIV-infected patients 
with lipodystrophy128.  Thirty HIV-infected participants without lipodystrophy were separately 
matched to 90 HIV-uninfected controls.  Participants were matched on age and BMI.  The study 
found that 35% of patients with lipodystrophy had impaired glucose tolerance.  HIV-infected 
cases with lipodystrophy were more likely to have impaired glucose tolerance than their matched 
HIV-uninfected controls (OR 6.5 adjusted for waist-to-hip ratio, 95% CI 2.9-14.7).  In addition, 
HIV-infected cases with lipodystrophy were more likely to have hyperinsulinemia (adjusted OR 
3.2, 95% CI 1.7-7.2).  Insulin levels and glucose levels did not significantly differ between HIV-
infected patients without lipodystrophy and their HIV-uninfected controls.  Selection bias may 
have affected results, as HIV-infected cases were responders to community-based advertisements 
or due to physician referrals and thus may differ from HIV-infected individuals who chose not to 
participate.  Likewise, controls were not chosen in a similar manner but, instead, were taken 
from a large population based study.    The varying results of the aforementioned studies 
underscore the difficulty in determining the exact prevalence and incidence rates of IR and IGT 
in HIV-infected populations.   
While the exact mechanism is not known, a number of theories have been proposed to 
help explain the cause of IR in HIV-infected populations102.  These mechanisms include direct 
metabolic effects from antiretroviral therapies129, 130, metabolic dysfunction due to HIV infection 
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itself secondary to cytokine and hormonal abnormalities, and an interaction between HIV disease 
and antiretroviral therapies128. 
 Numerous studies found an association between protease inhibitor use (specifically 
indinavir, amprenavir, nelfinavir, and ritonavir) and the development of IR116, 131-135. These 
results have been strengthened by studies showing that switching patients to other regimens 
improved the hyperglycemia136, 137. The use of PIs has been shown to lead to abnormal lipids and 
glucose metabolism even in the absence of HIV132, 138.  For example, Noor et al found that 
indinavir reduced insulin sensitivity by 38% after a single dose in healthy, HIV-uninfected 
individuals132. Although the mechanism is not fully understood, current literature suggests that 
PIs may lead to insulin resistance by interfering with glucose transport and phosphorylation130. 
Others propose that PI regimens cause peripheral IR in skeletal muscle and adipose tissue as well 
as impair the ability of the beta cells to deal with these changes by reducing pancreatic beta cell 
insulin secretion134, 135, 139. In addition, PIs have been shown to inhibit GLUT4, a necessary rate-
limiting step in the transport of glucose across cell membranes, thus decreasing the glucose 
regulating ability of GLUT4 with subsequent increases in cellular glucose uptake100. Other drug 
regimens such as nucleoside analogues may not directly affect glucose metabolism but still may 
contribute to IR through body fat distribution changes135. 
While the majority of literature does indicate that a relationship exists between PIs and 
IR133, 134, 140,  a number of studies found contradictory results suggesting that other medications, 
factors related to HIV, and traditional IR risk factors may be of importance141.  Hadigan et al 
reported similar increases in fasting and 2-h insulin levels among PI-naïve patients as well as in 
both current and past recipients of PI therapy128.  They also found that the duration of NRTI 
exposure but not duration of PI exposure predicted fasting hyperinsulinemia in multivariate 
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regression analysis and proposed that a more complex pathophysiologic mechanism for 
metabolic abnormalities exists.   Howard et al, also did not find a significant association between 
PI use and IR likely due to the lower number of men on indinavir (13%) compared with other PIs 
that have a weaker effect on the development of IR109, 131, 132, 142-146. A larger, prospective cohort 
study by Brown et al assessed IR and its relationship to HAART in a cohort of HIV-infected and 
uninfected men and found that of the 3 major drug classes, only cumulative exposure to NRTI 
was independently associated with fasting hyperinsulinemia (OR 1.08; 95% CI 1.02-1.13) 
although cumulative exposure to PIs had a similar, but non-significant relationship (OR 1.06; 
95% CI 0.99-1.14) 141.  It is possible that the lack of association with PIs in the above studies is 
due to the heterogeneous effect of protease inhibitors on IR.  Grouping PIs together as class 
rather than assessing the effect of the individual PI may dilute any effect of the individual 
medication141.  It is also important to recognize that studies focusing on cumulative or long-term 
drug effects may report conflicting results compared with those focused on recent drug exposure 
as PIs (specifically indinavir) typically lead to an acute onset of IR which is reversible after drug 
discontinuation11. 
1.2.5.3 Risk factors for glucose disorders in HIV-infected populations 
While the mechanism for DM onset in HIV-infected populations is unknown, many authors 
speculate that protease inhibitor use plays a role due to insulin resistance32, 100, 110, 129, 133, 134, 147, 
148.  The rate at which IR and IGT progress to DM in HIV-infected individuals is not fully known 
and because insulin resistance from PIs is reversible, other risk factors for DM should be 
considered11, 137.  Limited data is available on the association of DM with NRTI use although 
studies do suggest that cumulative exposure to this drug class may be associated with glucose 
disorders11, 14, 125, 128, 141, 149.  The mechanism for this association is under investigation and may 
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involve inhibition of mitochondrial DNA polymerase-gamma150. It is possible that chronic HIV 
infection (due to prolonged inflammation and cytokine over expression)103, 151, 152, and  risk 
factors that are more specific to HIV-infected populations including hepatitis C virus infection 
(HCV)122, 123, 153, drug-drug interactions12, 110, 152, lipoatrophy and body fat redistribution110, 128, 
149, 154, 155, and a history of an AIDS defining illness14, 107, 123, 153 may play a role in DM and IR 
development.  However, it is important to note that risk factors vary from study to study 
depending on population, sample size and study design.  For example, Mehta et al found that 
HCV infection was associated with hyperglycemia and DM123 whereas Hughes et al12 did not 
find an association and results from Ledergerber et al were inconclusive14.   Further, Brar et al 
did not find an association between HCV coinfection and DM in HAART naive individuals107.  
Differences in HCV study populations such as younger age in the Hughes study and a larger 
percentage of minority participants in the Mehta study may explain these discrepancies as well as 
power differences based on sample sizes and variations in drug therapy.  This example illustrates 
the difficulty of defining the risk factors associated with new onset DM and IR in HIV-infected 
populations.  
Regardless of these discrepancies, findings from numerous studies underscore the 
importance of traditional risk factors in the development of DM in HIV infected populations107-
109. Factors such as older age11, 12, 14, 107, 109, 123, 148, 153, higher BMI11, 107-110, 156, 157, black or 
Hispanic race11, 12, 14, 107-109, 153, family history of DM108, 109, 156 and male sex11, 14 were 
consistently associated with DM in HIV-infected populations regardless of study design, 
population, or sample size.   
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1.2.6 Physical activity in HV-infected populations 
1.2.6.1 Prevalence 
In the general population, it is well accepted that a physically active lifestyle helps prevent many 
chronic diseases and conditions.  Less is known about the risks and benefits of physical activity 
participation in HIV-infected individuals158. In fact, most of the studies have focused on exercise, 
a subset of PA159.  Early studies suggest that physical activity can be implemented safely in HIV-
infected populations, however results should be interpreted cautiously due to small sample 
sizes160-169, high dropout rates160, 165, 166, 168-170, and lack of an HIV-uninfected control group160, 
164, 165, 167-169 or a non-exercising control group165, 169.  A 2004 meta-analysis by O’Brien et al was 
not able to confirm an overall effect of aerobic exercise on CD4, viral load, or VO2max, however 
they reported the possibility of clinically important improvements in VO2max in exercisers 
compared with non-exercisers171.  They attributed the lack of statistical significance to small 
sample sizes and concluded that aerobic exercise for HIV-infected adults appears to be safe due 
to the stability of immunological and virological measures as well as the absence of adverse 
event reports among exercisers in the included studies171.  Mustafa et al reported that exercise 
was associated with slower progression to AIDS at 1 year (HR= 0.68, 90% CI 0.4-1.17).  An 
increase in CD4 count by 107% during the year was also reported compared with non-
exercisers172.  The authors did not adjust for other factors in their models; therefore it is possible 
that improvements in CD4 count were due to factors such as medication adherence or better 
medical care.  Despite these limitations, the fact that exercise appeared beneficial rather than 
harmful to CD4 count deserves attention.  Bopp et al were the first to assess the effect of daily 
physical activity on CD4 cell counts and viral load in HIV-infected individuals and reported a 
significant, inverse association between PA levels (measured by wrist actigraph) and viral load  
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(r = -0.425, p=0.0061)173.   Although the cross-sectional design limited the ability to make causal 
inferences, the results do provide some evidence that HIV-infected persons who partake in 
regular physical activity may incur health benefits compared with their more sedentary 
counterparts.  Current exercise recommendations for HIV-infected persons support the safety and 
efficacy of moderate to high intensity aerobic and resistance training if prescribed by a trained 
professional174.  
 A few studies have assessed the prevalence of overall physical activity participation in 
HIV-infected populations159, 175-180 and results varied greatly based on study population (Table 
1).  None of the studies were population based, making comparisons with the general population 
as well as the overall HIV-infected population difficult.    
Arendt et al, reported a higher prevalence of activity in HIV-infected men than in 
Canada’s general population (84.5% versus 56%)175.  However, comparability is limited as 
participants in this study may not be representative of the general HIV-infected population (study 
consisted of white homosexual or bisexual men).    
 Filipas et al reported that nearly three quarters (73.8%) of their HIV-infected population 
met CDC and American College of Sports Medicine Guidelines (ACSM) for PA while 65.8% of 
their HIV-uninfected population met the guidelines177.  However, this study had several 
limitations including a small sample size, limited demographic data, possible misclassification of 
HIV-uninfected participants (based on self-report only) and use of the International Physical 
Activity Questionnaire (IPAQ) which tends to overestimate physical activity levels179, 181. In an 
IPAQ validation study, Ramirez-Marrero et al179 compared self-reported PA levels from the 
IPAQ with objective PA measures including accelerometer use and found that the IPAQ 
significantly overestimated moderate and vigorous PA compared with the Actigraph (mean 
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difference -268.6 + 314.0 min/wk IPAQ > Actigraph, t = - 6.16, p< 0.01) in a sample of HIV-
infected Hispanic adults.  The proportion of participants who were classified as physically active 
(defined as > 150 min/wk of moderate to vigorous PA) was 81% when using the IPAQ compared 
with 54% based on Actigraph data.  Overestimations of PA were more frequent in men (72%) 
than in women (43%).  This is the only study using an objective physical activity measure; 
therefore prevalence estimates are likely more accurate than estimates based on self-report.  
Unfortunately, the sample size was small and subjects from the parent study were not randomly 
chosen for participation.  Larger, randomized studies are needed to verify their results.  A cross-
sectional study by the same authors found that HIV-infected participants reported participation in 
1.5 hours/day of physical activity with 59% meeting the minimum PA recommendations of 30 
minutes daily; however over reporting in this study was possible due to inconsistencies with 
reported amounts of hours spent watching television (up to 5.9 hours/day) as well as reports of 
minimal daily exertion (based on the Leisure Activity Inventory)182.   
 Smit et al reported lower levels of vigorous PA in HIV-infected participants using 
HAART compared with HIV-uninfected participants and HIV-infected participants not using 
HAART suggesting a possible lower intensity PA tolerance among HAART users; however no 
significant differences in overall PA levels were found (p=0.26)180. Due to the cross-sectional 
design of the study, temporal inferences regarding HAART use and activity levels cannot be 
made.  In addition, a greater proportion of HAART users had clinical AIDS (21.64% non 
HAART versus 15.19% HAART) and were less likely to be employed (25.32% non HAART 
versus 18.94% HAART) therefore it is possible that HAART users were more limited in PA due 
to illness.  Muhammed et al also found that HIV-infected participants reported higher levels of 
PA than HIV-uninfected counterparts, however these results were not representative of the 
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general population as all participants had Nonalcoholic Fatty Liver Disease178.  In addition, 
sample sizes were very small and HIV-infected participants were generally healthier with lower 
proportions of DM, hypertension and cardiovascular disease, which may partially explain the 
higher PA levels.  Clingerman found that, while the majority of her Canadian HIV-infected 
population participated in some form of PA, only 28% met the Healthy People 2010 
recommendations for moderate activity (at least 30 min 5 or more days per week) and even less 
(19.2%) met the vigorous activity recommendations (at least 20 min 3 or more days per week)176.  
39.7% did not meet any of the recommendations.  This study also had a small sample size and 
did not have an HIV-uninfected control group making interpretation of results limited.   
 Florindo et al reported that 65% of HIV-infected men and women participated in 
“adequate” locomotion physical activity while 47.3% participated in leisure physical activity.  
Unfortunately, the authors do not define “adequate” so estimates may not be comparable to other 
studies183.  Using the Minnesota Leisure Time Physical Activity Questionnaire, Domingo et al 
reported a physical activity prevalence of approximately 30% in HIV-infected participants living 
in Barcelona, Spain184.  Again, small sample sizes and a lack of an HIV-uninfected group limit 
interpretation of results.   
  Finally, the Howard studies108, 109 also found much lower prevalence estimates (> 70% 
classified as inactive) as did Danoff et al120 and Mustafa et al172; however it is important to note 
that the definitions of physical activity were limited to exercise and may not capture other forms 
of activity done throughout the day such as walking at an occupation or for transportation.  Their 
estimates likely underestimate the true PA prevalence based on this definition.  
 In general, the studies indicate that a significant number of HIV-infected persons do 
participate in some form of regular physical activity, although larger population studies are 
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needed to get more accurate prevalence estimates.  The cultural diversity of the studies indicates 
that participation is occurring on a somewhat global scale, although estimates from developing 
nations are not available.  The current studies have limitations such as small sample sizes, 
selection bias, reporting bias, mostly male participants, and lack of an HIV control group which 
make comparisons with the general HIV-infected population difficult.  Given the clinic-based 
populations used in the aforementioned studies, it is possible that the HIV-infected participants 
in these studies represent a healthier and thus more active subset compared with the general 
HIV-infected population.   In addition, all but one of the studies used self-reported PA measures 
possibly resulting in a reporting bias and a potential overestimation of PA prevalence.  Studies 
using objective PA measures such as an Actigraph accelerometer are necessary to better 





Table 1. Physical activity prevalence studies in HIV-infected populations 
Author, year Study design Study population PA Measurement Results 
Arendt 
(2008) 
Cross-sectional 65 HIV-infected men 
from the University 
Health Network, 
Toronto, Canada with 
at least one feature of 
metabolic syndrome 
(mean age 47) 
7 day PA log 84.5% met Canada’s PA 
Guide (60 min of mild or 
30-60 min of moderate 
activity per day) 
 
41.4% sedentary using the 
classification of the Institute 
of Medicine 
 
More active than general 
Canadian Population 
(44.1% physically inactive) 
Fillipas 
(2008) 
Cross-sectional 191 HIV-infected 
patients and 70 HIV-
uninfected patients 
(with non HIV 
infectious disease) 
from Infectious 
Disease Clinic of The 
Alfred hospital, 
Melbourne Australia, 





73.8% of HIV infected and 
65.8% of HIV-uninfected 
participants met Centers for 
Disease Control and 








Hispanic adults from 
the AIDS Clinical 
Trials Unit in Puerto 





(> 150 min/wk of moderate 
to vigorous PA) 
: 81% classified as 
physically active  
Actigraph
(> 150 min/wk of moderate 
to vigorous PA) 
: 54% classified as 
physically active  
Pedometer
(> 10,000 steps/day) 
: 17% classified 
as physically active  
Mohammed 
(2007) 
Cross-sectional 26 HIV-infected (age 
46.2) and 25 HIV-
uninfected men (age 
43.1) with 
Nonalcoholic Fatty 
Liver Disease from 
University Health 
Network clinics 
7 day PA log Physical activity was 
significantly higher in the 
HIV-infected group (8 units 
per day) compared with the 
HIV-uninfected group 
(4 units per day) (p=0.029)  
Florindo 
(2007) 
Cross-sectional 220 HIV-infected men 
and women from the 








65% of participants reported 
adequate locomotion 
physical activity (70.6% 
women and 63.3% men) 
47.3% participate in leisure 
physical exercise 
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Table 1. (continued) 
Author, year Study design Study population PA Measurement Results 
Smit  
(2006) 
Cross-sectional 324 subjects (213 
HIV- infected with 
mean age 42 and 99 
HIV-uninfected with 
mean age 46) from the 
AIDS Linked to 
Intravenous 
Experiences (ALIVE) 
cohort (mostly African 
American cohort of 






expenditure was lower 
among participants on 
HAART (267 kcal/day) than 
both HIV-uninfected (438 
kcal/day) and HIV-infected 
participants not on treatment 
(623 kcal/day) however 
total energy expenditure did 
not significantly differ 
between groups (p=0.26) 
Howard 
(2006) 
Cross-sectional 279 HIV-uninfected 
men and 364 HIV-
infected men (mean 
ages 54) (N=643) 






strenuous for > 20 
minutes on > 1day 
per week 
29% of HIV-uninfected men 
were classified as physically 
active while 30% of HIV-
infected men were 




Cross-sectional 288 HIV-uninfected 
women (mean age 45) 
and 332 HIV-infected 
women (mean age 44) 
(N=620) 






strenuous for > 20 
minutes on > 1day 
per week 
23% of HIV-uninfected 
women were classified as 
physically active while 20% 
of HIV-infected women 
were physically active 
(difference not significant) 
Danoff 
(2005) 
Cross-sectional 258 women: 
88 HIV-uninfected 
(mean age 37.6), 74 
HIV-infected not on 
HAART (mean age 
37.6), 
96 HIV-infected on 





Urban U.S.  
Self-reported 
physical activity 
defined as > or < 6 
hours per week 
 
54% of HIV-uninfected 
women participated in > 6 
hours compared with 56.2% 
of HIV-infected women not 
on HAART and 46.3% on 
HAART. 
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Table 1. (continued) 




Cross-sectional 68 HIV-infected men 
(n=43) and women 
(n=25) recruited from 
the AIDS Clinical 







41% of HIV-infected adults 
did not meet the minimal 
PA recommendation 
 
Time spent in daily physical 
activity was an average of 
1.2 hours per day with most 
of the reported activities 
occupational 
 
32% reported participating 




Cross-sectional 78 HIV-infected men 
(n=70) and women 
(n=8) ages 23-70 years 
who received primary 
care at an infectious 
disease clinic or 
community support at 
a local agency 
(Northern Great Lakes 




73.08% of participants 
engaged in moderate PA 
while 19.2% engaged in 
vigorous PA 
 
51.7% participated in PA 
for recommended weekly 
frequency. 
 
28.2% met Healthy People 
2010 recommendations for 




39.7% did not meet any of 





Cross-sectional 120 HIV-infected men 
and women (mean age 
39) recruited from 
participants in a cross-







28.0% of participants 
physically active ( >143 
kcal/day) using stavudine 







(mean age 35) and 259 
HIV-uninfected (mean 
age 37) men 
participating in The 
Longitudinal AIDS 




“How many times 
a week do you 
engage in physical 
exercise?”  
29% of HIV-infected and 
28% of HIV-uninfected men 
were non-exercisers 
35% of HIV-infected and 
31% of HIV-uninfected men 
exercised daily 
36% of HIV-infected and 
41% of HIV-uninfected men 
exercised 3-4 times/wk 
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1.2.6.2 Prevention of diabetes in HIV-infected populations 
Because PA and exercise are cost-effective health promotion interventions that could decrease 
the need for health care resources, slow HIV disease progression, and prevent or delay the onset 
of chronic conditions, the role of physical inactivity as risk factor for DM in HIV-infected 
persons deserves attention given the prevalence of HIV-infected populations already 
participating in regular physical activity32, 100, 129, 133, 134, 147, 175-177, 180. Unfortunately, the majority 
of the studies assessing risk factors for DM in HIV-infected populations did not account for 
levels of physical activity, an important risk factor for DM in HIV-uninfected populations11-14, 
107. Therefore, the results of previous studies that observed an association between HAART use 
as well as other non-traditional risk factors and DM/IR might have been confounded by PA 
levels.  Brar et al clearly state in their manuscript introduction that studies aimed at 
understanding the risk factors associated with DM in HIV-infected populations discount 
traditional “classic risk factors” yet in their study assessing risk factors for DM among ART 
naïve participants, they do not account for physical activity levels (although the authors do 
recognize this limitation)107.  Similarly, Hughes et al and Palacios et al emphasize the importance 
of traditional risk factors in the development of DM in HIV-infected populations, yet did not 
assess physical activity12, 110.  Further, the newly released European AIDS Clinical Society 
guidelines on the prevention and management of metabolic diseases in HIV acknowledged the 
limited amount of available literature with respect to PA and DM and base their physical activity 
recommendations for the prevention of DM on “extrapolations from general medical 
guidelines185.”  
Only 4 studies have addressed associations between physical activity with DM and IR in 
HIV-infected populations (Table 2).  Howard et al define “physical activity” as moderate or 
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strenuous exercise for > 20 min on > 1 day/week108, 109.    Among their participants, 70% of both 
HIV- uninfected and HIV-infected men were inactive while 79% of women were inactive.  They 
found that physical inactivity was associated with previously diagnosed diabetes in HIV-
uninfected and HIV-infected women (OR 0.4, 95% CI 0.2-0.96); however this result was not 
replicated in their study of HIV-infected men (OR 0.6, 95% CI (0.3-1.4).  The discrepancy in 
findings may be attributed to the demographic differences between the two cohorts given the 
comparable study designs and sample sizes.  Risk factors such as black or Hispanic 
race/ethnicity and older age could potentially have overridden any PA effect among the male 
cohort.  In comparison, the female cohort had younger mean age (by 10 years) as well as a lower 
percentage of individuals of black or Hispanic race/ethnicity potentially allowing for an 
increased PA effect.  Conversely, Danoff et al did not find an association between PA and DM in 
their cross-sectional study of 258 HIV-infected and HIV-uninfected women120.  However, the 
sample size was small and power may have been limited.  Further, PA was defined differently  
(< or > 6 hours of exercise per week) than in the Howard study, making comparisons difficult.  
The smallest of the 4 cross-sectional studies evaluated the association between IR and habitual 
exercise in a cohort of 120 HIV-infected individuals186. The authors report a significant 
independent and inverse relationship between total exercise (defined as number of sessions per 
week x duration per session x intensity) and IR (std β = -.20, P=0.03).  In contrast to the 3 other 
studies, their cohort consisted of mostly white individuals with a lower than average BMI, a 
large proportion of whom participated in some form of exercise.  Therefore, participants may 
have started with a lower background DM risk profile.  Despite a paucity of literature, regular 
PA is recommended for HIV-infected individuals with IR and DM; therefore it is possible that 
individuals with IR in that study were encouraged to exercise potentially leading to their 
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observed results187.  Finally, they lacked an HIV-uninfected control group and were thus unable 
to control for HIV status in their multivariate analysis. 
Limitations do exist in the current literature.  All 4 of the studies were cross-sectional and 
therefore were unable to assess any causal relationship between physical activity and the 
development of DM and IR.  It is possible that low physical activity is a result of the diabetes, 
rather than a precursor to its onset or that that PA activity was started based on doctor 
recommendations to manage IR and DM187. Recent literature implies that the presence of 
diabetes may independently contribute to impaired exercise capacity188. Left ventricular 
dysfunction 188, aging, female sex, poor diabetes control, reduced heart rate recovery, obesity189, 
190, race190, impaired femoral arterial blood flow191, and impaired exercise stroke volumes192, as 
well as microvascular diabetic complications including neuropathy and retinopathy193 may be 
associated with impaired exercise capacity in individuals with type 2 diabetes.  Regensteiner et 
al, also observed a reduced rate of oxygen consumption increases during treadmill testing of 
healthy patients with non-insulin dependent diabetes, indicating that oxygen delivery limitations 
may lead to impaired exercise performance194.  
Secondly, three of the studies used cohorts that included a majority of individuals at very 
high risk for DM due to older age, higher BMI, black/Hispanic ethnicity, and lower levels of 
PA108, 109, 120.  In addition, all 4 studies were conducted in urban or inner city sites in the United 
States.  Thus results may not generalize to HIV-infected populations at lower risk for DM.  Two 
of the studies used self-reported DM as their outcome rather than measuring glucose levels for 
all participants while the other studies did not confirm glucose levels on a subsequent visit108, 109.   
Finally, it is important to note that none of the 4 studies measured physical activity in its entirety 
but rather focused exclusively on exercise, a subset of PA.  This is important because it is 
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possible that an individual was physically active throughout the day (i.e. at an occupation, 
completing housework, walking for transportation, etc) without actually participating in 
structured exercise16. Therefore, results may actually underestimate a true PA effect.  
Conversely, a reporting bias due to the use of self-report exercise may have lead to an 
overestimation, especially in the Gavrila study, which had a large proportion of individuals who 
reported exercise participation186.   
Due to the paucity of literature as well as limitations in the current literature, large 
prospective cohort studies or randomized trials, similar to those completed in HIV-uninfected 
populations are necessary to assess the role of PA in the prevention of DM and IR in HIV-
infected populations.  Further, these studies must use validated physical activity questionnaires 
or objective PA measures to accurately assess the PA levels (including exercise) of the study 






Table 2. Studies assessing physical activity as a risk factor for diabetes and insulin 



















(mean ages 54) 
(N=643) 
54 HIV-uninfected 
men and 126 HIV-
infected men for 
metabolic 
substudy (mean 
ages 54) (N=216) 













> 20 minutes 
on > 1day per 
week 
DM risk factors: use of non-PI HAART 
(OR 1.8, 95% CI 1.03-3.0), current 
methadone treatment (OR 6.7, 95% CI 
3.8-11.9), alcoholism (OR 1.7 95% CI 
1.1-2.7), high BMI (OR 1.4, 95% CI 
1.8-6.2), and family history of DM (OR 
3.5, 95% CI 2.2-5.6) 
Metabolic substudy IR risk factors: 
waist circumference (p<0.0001) and 
history of heroin use (p=0.005) 
Abnormal OGTT risk factors
*Physical activity not associated with 
DM or IR 
: age > 55 
(OR 2.0 95% CI 1.03-3.9), Hispanic 





258 women:  
88 HIV-uninfected 
(mean age 37.6), 
74 HIV-infected 
not on HAART 
(mean age 37.6), 
96 HIV-infected 


















> or < 6 hours 
per week of 
exercise 
DM risk factors
 (OR 1.104, p < 0.0002) 
: BMI (per kg/m2) 
 
*Exercise not associated with DM or 
IR 
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(mean age 45) and 
332 HIV-infected 








ages 44 and 45 
respectively) 
(N=216) 













strenuous for > 
20 min on > 
1day per week 
DM risk factors: current methadone 
treatment (OR 1.8, 95% CI 1.01-3.3), 
high BMI (OR 2.6, 95% CI 1.04-6.7), 
family history of DM (OR 2.7, 95% CI 
1.6-4.7), and physical activity (OR 0.4, 
95% CI 0.2-0.96) 
Metabolic substudy IR risk factors: 
waist circumference (p<0.0001), 
Hispanic ethnicity (p=0.01), and PA 
(p=0.03) 
Abnormal OGTT risk factors
Gavrila 
(2003) 
: age > 50 
(OR 3.8 95% CI 1.3-11.2), family 
history of DM (OR 2.7, 95% CI 0.1-
0.6), PA (OR 0.2, 95% CI 0.1-0.6), and 
smoking (OR 1.5 per 10 pack-years, 





















*significant inverse association 
between total exercise and IR 




1.2.6.3 Management of glucose disorders 
A few small prospective studies and clinical trials have investigated the role of exercise on 
glucose and insulin reduction in HIV-infected populations with varying results111, 195, 196.  
Driscoll et al randomized 42 HIV-infected participants to one of two treatment groups 
(metformin alone and metformin + exercise).  Participants in the exercise arm completed 3 
months of an aerobic and resistance training program.  Significant differences for fasting insulin 
(p=0.03) were reported between the two treatment groups196. The metformin + exercise group 
had a greater decrease in insulin levels from baseline compared with the metformin alone group.  
Conversely, in their randomized trials of 40 HIV-infected women and 42 HIV-infected men and 
women, Dolan et al and Terry el al did not find significant reductions in fasting glucose levels 
between an exercise group and the control group169, 197, 198.  Similarly, Thoni et al did not find 
significant differences from baseline in fasting insulin, fasting glucose, or insulin resistance 
levels after completion of a 16 week aerobic training program in 19 HIV-infected adults (p-
values not reported)199.  In a prospective study of 18 men with HIV-infection no significant 
reductions in insulin were noted after completion of a 16 week resistance training program200. 
Finally, Fitch et al randomized 34 men and women with HIV-infection and metabolic syndrome 
to a lifestyle intervention, modeled after the Diabetes Prevention Project intervention, and to a 
control group111.  Fasting glucose levels and hemoglobin A1C percentage did not significantly 
change in the lifestyle group when compared with the control group.  Insulin levels and IR 
(HOMA) improved in the subjects in the intervention group compared to the control group; 
however the results were not significant due to small sample sizes.   
Significant limitations in this literature restrict the interpretation of results.  None of the 
studies utilized an HIV-uninfected control group; therefore the effect of HIV cannot be 
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examined.  Sample sizes were very small in all studies and power to detect differences was 
limited.  All of the studies recruited participants from clinics so results cannot be generalized to 
the general HIV-infected population.  Measures such as HbA1c were not assessed in 3 of the 
studies therefore the effect of the activity on direct glycemic control is not fully known.  None of 
the studies used participants with diagnosed type 2 DM, so the effect of exercise on potentially 
higher baseline fasting glucose and insulin levels in HIV-infected populations is also unknown.  
In addition, the studies were all very short (6 months or less) compared to those completed in the 
general population.  Larger and longer population based intervention trials are necessary to fully 
understand the effect of exercise and physical activity on the management of DM and IR in HIV-
infected populations. 
1.2.7 Physical activity and physical function correlation 
1.2.7.1 HIV-uninfected populations 
Although related, physical activity and physical function have differences.  Physical activity is 
defined as any voluntary movement produced by the skeletal muscles that results in increased 
energy expenditure201, whereas physical function is defined as one’s ability to carry out various 
activities that require physical capability, ranging from self-care (activities of daily living) to 
more vigorous activities that require increasing degrees of mobility, strength, or endurance202. 
Physical activity is associated with reduced risk of mortality, onset of diseases, and incident 
disability while maintaining physical function is of great importance to successful aging18, 203, 204. 
Despite these differences, numerous cross-sectional and prospective studies in HIV-uninfected 
populations established that physical activity levels are correlated with physical function 
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performance and that low physical activity is a risk factor for declines in physical function15-18, 
201, 203-210. 
While prior studies in aging populations utilized self-report measures only206-211, Brach et 
al observed a correlation between objective physical activity measures (pedometer) with the 
Functional Status Questionnaire (FSQ) (a self-report measure of physical function) (r=0.34, 
p<0.01) and the Physical Performance Test (PPT) (a comprehensive performance-based measure 
of function) (r=0.41, p< 0.01) in a cohort of 290 community dwelling older women15. 
Correlations for the aforementioned physical function measures with a self-report physical 
activity questionnaire (Modified Paffenbarger) were also reported (r=0.34, p < 0.01 for the FSQ; 
r=0.16, p <0.05 for the PPT; r=0.24).    It is important to note that this study excluded women 
with physical limitations that might have prevented walking and thus the women participating in 
this study were functioning better than 90% of the community-dwelling older adults.  In addition, 
the majority of women was of upper social and economic class and was Caucasian. Therefore, 
results may not generalize to more disadvantaged populations.   
Studies are not limited to geriatric populations.  A recent study of 8,702 U.S. and 1,507 
British middle-aged adults (aged 50 to 69), found that physical activity was protective against 
impaired physical function (self-report and measured) independent of BMI205. Participants who 
reported > 3 days of activity per week had a lower incidence of physical impairment than 
individuals who reported less activity in each BMI category (recommended weight, overweight, 
obese). Hillsdon et al also showed that regular physical activity (defined as 2.5 hours per week of 
moderate PA or > 1 hour of vigorous activity per week) was associated with higher self-reported 
physical function (OR 1.6, 95% CI 1.3-1.98 adjusted for age, gender, chronic illness, baseline 
PF, BMI, smoking, and SES) in a cohort of 6,398 middle aged men and women (aged 39 to 63 
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years) 18.  Despite the lack of objectively measured physical activity, these studies are important 
because they extend the protective effect of physical activity on physical function to slightly 
younger populations. 
 Although less common, studies have also shown that individuals with impaired physical 
function and lower perceived physical function are less likely to participate in regular physical 
activity.  According to the U.S. Department of Health and Human Services national survey data, 
people with physical disabilities and chronic illness were less likely to report participation in 
moderate physical activity than their healthy counterparts (27.2% versus 34.4% participation) as 
well as vigorous physical activity (9.6% versus 14.2% participation)39.  Similarly, according to 
Healthy People 2010212, 56% of individuals with disabilities reported no leisure-time PA 
compared to 36% without disabilities.  Only 12% of persons with disabilities reported 30 min of 
moderate PA 5 or more days per week212. 
 In a study of 2311 men and women with diabetes, Plotnikoff et al found that higher levels 
of physical activity were independently associated with lower levels of perceived disability 
among individuals with type 1 (β = -0.22, P<0.001) and type 2 diabetes (β = -0.18, P<0.001) 213.  
Due to the cross-sectional study design, causal inferences between impaired physical function 
and physical activity could not be addressed.  In addition, the study did not use an objective 
measure for physical function or physical activity, instead relying on self-report.  The potential 
for reporting bias exists.  A stronger, longitudinal study by the same authors produced similar 
results214.  Participants with diabetes who reported less difficulty in completing tasks of daily 
living were more likely to participate in higher levels of physical activity (β = -0.08, P<0.001 in 
type 2 diabetes and β = -0.12, P<0.001 in type 1 diabetes).   
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 These findings demonstrate that, although different, physical function and physical 
activity are associated with one another.  The data suggest that physical activity participation not 
only predicts physical function but is also lower among individual with functional limitations 
and disability. 
1.2.7.2 HIV-infected populations 
Similar studies have not yet been completed in HIV-infected cohorts in the post-HAART era; 
therefore the relationship between physical activity and physical function in this population is 
unknown. A pre-HAART randomized trial assessed the effectiveness of a 15-week home based 
aerobic exercise program on health related quality of life measures, including physical 
function160. One hundred twenty three HIV-infected subjects were randomized to a control group 
or an exercise group.  Physical function was measured using the Medical Outcomes Study HIV 
Health Survey.  Following the 15-week exercise program, no significant difference in physical 
function was reported between the control group and the exercise group (p=0.47).  Of note, non-
exercisers tended to report lower physical functioning (89.6% versus 86.5% in the exercise and 
control group respectively).  These results, however, are limited to aerobic exercise only and do 
not encapsulate physical activity as a whole.  Results must be interpreted with caution because 
occupational physical activity levels were not assessed and may have confounded results if 
differences between groups existed.   
In a small prospective study of 6 men with AIDS wasting and 19 men and women with 
HIV infection but without wasting, Roubenoff and Wilson, reported an increase in physical 
function status in patients with HIV wasting who completed a resistance training program21.  Of 
note, this study did not assess overall physical activity, but rather a progressive resistive training 
program.  Further, an HIV-uninfected control group was not included and sample size was small.  
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Clinical predictors for current levels of function and declines in physical functioning among 
individuals with AIDS were evaluated in studies by Wilson et al; however physical activity was 
not one of the variables that was assessed215, 216.  In addition, these studies were completed prior 
to HAART introduction.  In light of the longer life expectancy and decreased morbidity due to 
HAART use99, factors need to be re-examined.   
Despite the lack of literature in HIV-infected populations, studies of the relationship 
between PA and physical functioning in cohorts with other chronic conditions have been 
completed.  Seeman et al reported that regular physical activity protected against declines in 
physical function in older adults (ages 70-79 years) with histories of hypertension, cancer, and 
cardiovascular disease217.  Similarly, Stewart et al reported that higher baseline levels of exercise 
were associated with better physical function both at baseline and after 2 years for individuals 
with chronic diseases218.  These findings underscore the importance of using PA to promote 
higher levels of physical functioning, even among those with chronic conditions217, 218. In light of 
these promising results, studies in individuals with chronic HIV-infection are warranted and 
similar effects should be possible.   
Older adults now comprise a greater proportion of HIV-infected individuals due to the 
success of highly active antiretroviral therapy as well as an increase in new infections among 
adults older than age 5099, 219.  It has become necessary to address not only HIV infection but 
also co- morbidities associated with the normal aging process.  In fact, Oursler et al 
demonstrated that co- morbid conditions were associated with impaired physical function 
independent of HIV status220.  Although the impact of HIV infection and aging on physical 
function is documented, the association of physical function with physical activity levels has not 
been assessed220. Maintaining physical function has been shown to be a key aspect of healthy 
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aging in the general population221 and will likely become more of a focus in HIV-infected 
individuals as HAART use continues to slow disease progression220.  Therefore, it is imperative 
to identify factors, such as physical activity, that promote independent and disability free 
functioning in persons aging with HIV.  
1.2.8 Relationship between self-report and performance-based measures of physical 
function 
1.2.8.1 HIV-uninfected populations 
Physical function can be measured using either self-report or performance-based measures.  Self-
report questionnaires are often used due to their low cost and ease of administration222.  
However, discrepancies between an individual’s perception of ability and actual ability do exist 
and self-report measures may be influenced by psychosocial factors including mood, 
expectations, attitudes, and psychological distress222, 223.  Performance-based measures have face 
validity and are sensitive to change over time yet likely depend on a participant’s motivation to 
perform the task and may not accurately reflect performance in daily life222.   
A number of studies have assessed the association between these two types of 
measurements among differing populations.  In general, the results across studies are comparable 
and suggest that, at most, performance-based measures are only moderately correlated with 
measures of self-report222, 224-227.  Correlation coefficients in studies among older adults, patients 
with low back pain, and patients with fibromyalgia were similar and generally ranged from 0.1 to 
0.6 depending on task and self-report survey used222, 223, 226, 228, 229. The lack of a stronger 
correlation is likely due to the fact that performance-based and self-report measures assess 
different aspects of the physical function construct226.  While performance-based measures 
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examine an individual’s actual ability to complete a task through performance observation, 
measures of self-report rely on an individual’s perception of his or her ability to complete the 
task226.  Given these results, it is reasonable to suggest that the most accurate measure of physical 
function may be a complementary approach using both self-report and performance-based 
measures as subjective measures may provide useful information beyond that obtained solely on 
observation226. 
1.2.8.2 HIV-infected populations 
To date, similar studies have not yet been conducted in HIV-infected cohorts, therefore the 
relationship between performance-based and self-report measures in this population is not 
known.  Clarifying this relationship may help to provide insight into the possible overlap 
between differing measures of physical function.  This is important to gain a comprehensive 
understanding of physical function among individuals with HIV infection and to establish 
whether both types of measurements are beneficial to fully explain an individual’s functional 
capacity. 
Studies have been conducted which characterize levels of physical function among HIV-
infected populations.  Simmonds et al utilize both performance-based and self-report measures in 
their study of 100 HIV-infected men and women on the differential influence of pain and fatigue 
on physical performance.   Yet, they do not assess associations between the two types of physical 
function measurements230. Their study suggests that, as a group, physical performance among 
HIV-infected individuals was much lower than “age-equivalent healthy patients.”  They report 
that their population took up to 4 times as long to complete a sit-to-stand task and walked 180 
meters slower than healthy individuals.  However, these results should be interpreted with 
caution as their study did not have an HIV-uninfected group and the authors do not describe 
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where they obtained the data from the “healthy patients” used in the aforementioned 
comparisons.  In addition, a large percentage of their population (48%) were classified as having 
AIDS and may represent a sicker and thus more functionally impaired cohort of HIV-infected 
individuals.   O’dell et al, in their cross-sectional analysis of 546 HIV-infected men with AIDS, 
found that 10% to 50% of men reported some degree of physical disability (based on self-report 
physical function using the HIV Health Assessment Questionnaire)231.  The disability scores 
were more severe with the completion of higher level instrumental activities of daily living.  It is 
important to note that this study was conducted in the pre-HAART era therefore these estimates 
may no longer be applicable.  In addition, because all participants had AIDS, results may not 
generalize to more healthy HIV-infected populations.  Finally, an HIV-uninfected group was not 
utilized so it is not known how these results compare to the general population.  Population 
based studies have also been conducted.  Crystal et al assessed self-reported physical functioning 
in 2836 participants in the HIV Cost and Services Utilization Survey (United States) using a 9-
item scale232.  They found that physical limitations were more prevalent in tasks which required 
higher levels of energy expenditure such as stair climbing (43% limitation) and walking greater 
than 1 block (26% limitation) compared with self care tasks such as bathing or dressing (14% 
limitation).  Protease inhibitor use was found to be associated with significantly less physical 
limitation (p< 0.05).  A similar study was conducted by Rusch et al among 762 HIV-infected 
members of the British Columbia Persons with AIDS Society233.  A fifteen-item questionnaire 
was used to assess how well individuals were able to manage typical daily tasks such as eating 
and walking one block.  Activity limitations were reported in the majority of respondents 
(80.6%).  A median of 3 limitations was reported.  A significant difference in the percentage of 
activity limitations was observed after stratification by CD4 count (p=0.041).   Limitations in 
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these studies do exist.  Both studies utilized measures of self-report physical function which may 
not accurately reflect an individual’s actual functional ability.  Self-reported measures are often 
influenced by psychosocial factors such as mood, cognition, expectations, reporting bias, 
attitudes, and emotional distress223, 230.  In addition, HIV-uninfected comparison groups were not 
used and a potential for selection bias existed, especially in the Rusch study which mailed 
questionnaires to potential participants. 
Two recent studies by Oursler et al found similar levels of physical functioning among 
HIV-infected and HIV-uninfected participants.  Their study of 889 HIV-infected and 647 HIV-
uninfected participants in the Veterans Aging Cohort 5-Site Study found no significant 
difference in the unadjusted mean physical disability score when stratified by HIV serostatus 
(p=0.4)220.  In addition, the proportion of participants who reported difficulties with basic ADLs, 
mobility, and vigorous activities was similar in HIV-infected and HIV-uninfected participants 
(p>0.05 for all activities).  Regardless of HIV status, a higher percentage of individuals reported 
difficulty in more physically demanding tasks such as heavy work or active sports (>50%) 
compared with basic ADLs such as dressing (<9%).  It is important to note that these results 
were unadjusted and that the HIV-infected population in this study was younger than the HIV-
uninfected population.  In addition, the physical function measure was based on self-report and 
thus may not reflect actual abilities.  However, a second study by Oursler utilized functional 
performance testing234.  A total of 32 HIV-infected and 47 HIV-uninfected men from the 
Baltimore VA participated.  Functional performance measures included grip strength, the 6-min 
walk test, and graded exercise testing on a treadmill.  HIV-infected men aged 40 years and older 
were found to have a 41% reduced VO2 peak compared to age and gender-matched controls; 
however the mean 6-min walk distance was reduced only 8% compared to expected values for 
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healthy adults (adjusted for age, gender, and BMI).  After stratification by age, only the middle-
aged HIV-infected subjects (50-59 years) had significantly reduced grip strength as compared to 
published values for healthy men of similar age (p=0.02).  No significant differences were 
observed in the younger (40-49 years) or older men (60-69 years) when compared with healthy 
men by age group.  Grip strength was reduced by 10% (41.3 kg vs 46.2 kg) in HIV-infected 
adults using a weighted average.  This study was limited by small sample sizes and a potential 
for selection bias as all participants were volunteers.  Thus, results may not be representative of 
all patients with HIV.  Finally, HIV-uninfected controls were selected to be free of co-morbid 
conditions as compared with the HIV-infected men who were not necessarily excluded based on 
the presence of conditions such as diabetes and coronary artery disease.  Therefore, it is possible 
that any observed differences are not solely due to HIV disease and results should be interpreted 
with caution.   
Finally, a study by Bauer et al compared measures of balance and gait between 78 HIV-
uninfected volunteers to 28 HIV-infected participants receiving no ARV therapy, 25 receiving 
only nucleoside analogue therapy, and 37 participants receiving HAART235.  They found no 
significant differences in measures of proximal strength (360 degree turn, time to complete 5 
chair rises) and gait speed and cadence between any of the groups.  This study differs from the 
Oursler studies in that the majority of participants were female.  A potential selection bias 
towards a healthier HIV-infected subset is possible as participants were chosen on a volunteer 
basis from an outpatient clinic.  Therefore, results may not be representative of the entire HIV-
infected population. 
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1.2.8.3 Physical function and glucose disorders 
Numerous studies suggest that glucose disorders such as diabetes are associated with functional 
impairment236-244.  Yet, few studies have assessed measures of physical function as risk factors 
for glucose disorders despite recent literature showing that the loss of muscle mass and strength 
with age is associated with type 2 DM238, 242.  None of these studies were conducted in HIV-
infected populations.  Lazarus et al examined the cross-sectional and prospective relationships 
between handgrip strength and fasting insulin levels in 655 men from the Normative Aging 
Study cohort245.  Although handgrip strength was not found to be significantly correlated with 
unadjusted fasting insulin levels (r=-0.06), a negative cross-sectional association was observed 
after adjustment for confounders (p=0.013).  Similarly, in their prospective analysis, higher 
baseline handgrip values predicted lower fasting insulin levels after twenty years (p=0.017).  The 
authors suggested that skeletal muscle weakness may serve as a marker for an increased risk of 
hyperinsulinemia and may ultimately predict the development of insulin resistance.  
Generalizability in this study is limited to males and it is important to note that markers of 
insulin resistance (i.e. HOMA or QUICKI) were not assessed. A cross-sectional study by Sayer 
et al assessed the relationship between grip strength and metabolic syndrome in 1684 men and 
women born in Hertfordshire United Kingdom.  The HOMA formula was used a marker of IR 
while DM and IGT were classified using a 2 hour glucose concentration.  They reported a 
significant association between lower handgrip strength and a higher 2 hour glucose (0.07 
standard deviation increase, p=0.001) and with an increased HOMA (0.05 standard deviation 
increase, p=0.008) independent of weight, levels of PA, and age.  Despite these results, it is 
important to note that a temporal relationship could not be established as this study was cross-
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sectional in design.  Larger prospective studies are necessary elucidate the role of physical 
function as a risk factor for IR and DM in both HIV-uninfected and HIV-infected populations.   
 
1.2.9 Summary 
It is well established that metabolic disorders including insulin resistance and diabetes mellitus 
are prevalent in HIV-infected adults.  Although the current dogma implicates HAART use, the 
true cause of these disorders remains unclear.  The effect of physical activity and physical 
function is glaringly absent from the majority of studies that assess risk factors for DM and IR in 
HIV-infected populations despite its known importance in HIV-uninfected populations.  
Therefore, previous studies may have been affected by uncontrolled confounding.   In addition, 
the relationship between self-report and performance-based measures of physical function in 
HIV-infected populations has not been defined.  As individuals age with chronic HIV infection, 
it is imperative to identify early predictors of glucose disorders in order to help prevent the 
chronic complications associated with their progression22.  This is especially important for 
individuals with HIV-infection who may already be at risk for physical disability due to HIV 
associated symptoms220. 
The objective of this dissertation is to define the role of measures of physical function, a 
correlate of physical activity, as risk factors for diabetes mellitus and insulin resistance among 
HIV-uninfected and HIV-infected men in the Mutlicenter AIDS Cohort Study and, further, to 
describe the association between self-report and performance-measures of physical function in 
order to gain a comprehensive understanding of physical function among individuals with HIV-
infection.   
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Aims:  This study investigated the association between self-reported physical function (as a 
surrogate for physical activity) and diabetes mellitus (DM) and insulin resistance (IR) among 
HIV-infected and negative men.   
Patients and Methods: 384 HIV-negative and 274 HIV-infected men from the Pitt Men’s Study 
contributed data.  DM was defined by fasting serum glucose levels.  IR was calculated using the 
homeostasis model assessment.  The Physical Functioning Ten Scale from the Short Form-36 
Health Survey measured physical function.  Multivariate logistic regression assessed the 
independent association between physical function and DM and IR. 
Results:  Physical function, older age, and black race were associated with DM in multivariate 
analysis.  Physical function/HIV interaction, older age, higher BMI, HIV infection, and black 
race were associated with IR in multivariate analysis. 
Conclusions:  This study suggests that self-reported low physical function is associated with DM 





The wide spread usage of highly active antiretroviral therapy (HAART) presented unforeseen 
clinical challenges within the dynamic HIV epidemic. As the paradigm of HIV treatment shifted 
from palliative care to chronic disease management, new metabolic complications surfaced 
including insulin resistance (IR) and diabetes mellitus (DM)102, 103.  A full understanding of these 
complications remains elusive, but may involve a combination of antiretroviral therapy and 
duration of HIV infection as well as lifestyle, body mass index (BMI), age, sex, and genetic 
predisposition111, 112.  Prospective studies in HIV negative individuals suggest that participation 
in physical activity plays a significant role in the prevention of type 2 DM and insulin 
resistance71, 246.  However, the role of physical inactivity as a contributing factor to the 
development of DM has been overlooked in most studies of HIV-positive populations.  The few 
studies that have assessed physical inactivity as a risk factor for DM yielded conflicting 
results108, 109.  Physical inactivity was found to be associated with previously diagnosed diabetes 
among HIV-positive women; however despite similar methods and sample sizes, this observation 
was not replicated in HIV-positive men108, 109.  These studies by Howard, et al used a high risk 
cohort of mostly older black and Hispanic individuals without a standardized assessment of 
physical activity.  Therefore results may not generalize to other ethnic populations108, 109.   
Although related, physical activity and physical function have differences.  Physical 
activity is defined as any voluntary movement produced by the skeletal muscles that results in 
56 
increased energy expenditure201, whereas physical function is defined as one’s ability to carry out 
various activities that require physical capability, ranging from self-care (activities of daily 
living) to more vigorous activities that require increasing degrees of mobility, strength, or 
endurance.  Despite these differences, numerous studies in HIV-negative populations established 
that physical activity levels are correlated with physical function performance.  Both cross-
sectional and prospective studies suggest that low physical activity levels are an independent 
predictor of low physical function15-20.  Among HIV-positive populations, resistance training has 
been shown to improve self-reported physical function in patients with HIV wasting21.  
Therefore, the use of physical function as a surrogate for physical activity is justified. 
Current studies document a substantial prevalence and incidence of DM in HIV-positive 
men.  Data from the Multicenter AIDS Cohort Study (MACS) reported a 14% prevalence of 
diabetes mellitus (DM) among HIV-positive men compared to 5% among HIV-negative men and 
an incidence rate of 4.7 cases per 100 person-years compared with an incidence rate of 1.4 cases 
per 100 person years among HIV negative men106.  There is also a greater reported prevalence of 
insulin resistance in HIV-positive patients with lipodystrophy (35%) compared to matched 
controls without HIV (5%)128.  This trend is also noted in HIV-positive patients without 
lipodystrophy (5.6% IR prevalence) as compared to controls (3.3 IR prevalence)128. 
Given the strong association between low physical activity and DM among HIV negative 
individuals as well as the known risk for DM and IR development in HIV-positive men, the role 
of low physical activity in the HIV-positive population warrants further investigation.  Therefore, 
the objective of this study was to investigate the role of self-reported low physical function as a 
surrogate for low physical activity as a potential contributor to diabetes mellitus and insulin 





2.3.1 Study participants 
All study participants were from the Pitt Men’s Study in Pittsburgh, PA, one of four clinical 
centers which contribute data to the MACS.  The MACS is an ongoing multicenter prospective 
cohort study of HIV infection in homosexual and bisexual men.  Briefly the MACS follows a 6-
month visit schedule and involves detailed data collection regarding medical history, physical 
examination, and collection of biological specimens. Institutional review boards at each site 
approved the MACS protocol, and each participant provided informed consent.  Further detail 
can be found in Kaslow et al247.  The MACS is currently in the 47th consecutive 6-month follow-
up period of the original cohort.   
The current study includes data taken after implementation of the MACS Metabolic 
Study in April 1999 (Visit 31) at which time fasting serum samples (fasting > 8 hours) were 
added to measure glucose and insulin levels and for use in diagnosing diabetes.  772 men from 
the Pitt Men’s Study were eligible for inclusion in this study.   Of these, 658 (384 HIV negative 
and 274 HIV-positive) participants had a fasting serum sample from which insulin and glucose 
concentrations were obtained. 
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2.3.2 Outcome Ascertainment-Diabetes Mellitus and Insulin Resistance 
For the purpose of this study, a diabetes outcome was defined by fasting serum glucose levels 
drawn at each bi-annual visit from April 1, 1999 through March 31, 2006.  The first visit at 
which a participant underwent a fasting serum determination was defined as the baseline visit. 
Participants with a fasting glucose of less than 100 mg/dl for all visits were classified as 
“normoglycemic”; participants with at least one fasting glucose level between 100 and 126 mg/dl 
were classified as “pre-diabetic”; and participants with at least one fasting glucose level of 126 
mg/dl and above were classified as having “diabetes.”  This diabetes definition was chosen based 
upon a similar definition used by recently published literature in HIV-positive cohorts106, 120.   
Using this definition, 86 men were classified as “diabetic.”  Of these 86, 38 had confirmed 
glucose levels of > 126 mg/dl at their next visit; an additional 8 were placed on diabetes 
medications and 9 had a second non-consecutive visit with a glucose measurement of > 126 
mg/dl.  Participants with glucose levels consistent with diabetes (> 126 mg/dl) at baseline were 
not excluded from analysis (n=10).   
Insulin concentrations were also obtained from the fasting serum samples with normal 
insulin defined as < 15 µU/ml and high insulin defined as >15 µU/ml based on the published 
normal range for the insulin assay used.  Insulin resistance was calculated using the homeostasis 
model assessment (HOMA): [fasting insulin (µU/ml) x fasting glucose (mmol/L)]/22.5248.  
HOMA-IR levels were further classified into a dichotomous variable for use in logistic 
regression based on the median level of 3 µU/ml x mmol/L. Glucose levels were converted to 
mmol/L by dividing mg/dl by 18. 
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2.3.3 Exposure-Self-Reported Physical Function 
The Physical Functioning Ten (PF 10) Scale from the Medical Outcomes Study (MOS) Short 
Form-36 (SF-36) Health Survey served as a surrogate for a measure of physical activity.    The 
SF-36 is one of the most widely used Health Related Quality of Life Instruments and 
consistently demonstrates high levels of both reliability (>0.70) and validity249. Specifically, for 
the PF 10, Jenkinson et al report a Cronbach’s alpha of 0.93250 while relative validity has been 
reported at 1.00251. 
This study includes data from PF 10 questionnaires administered at each bi-annual visit 
from April 1, 1999 through March 31, 2006 (except visit 43: April 1, 2005 through September 
30, 2005).  During the administration of the PF-10, participants were asked the following 
question regarding physical activities that might be done in a typical day: “Does you health now 
limit you in these activities?  If so, how much?”  Participants chose between “Yes, limited a lot”, 
“Yes, limited a little”, or “No, not limited at all” for vigorous activities (running, lifting heavy 
objects); moderate activities (vacuuming, golf); lifting or carrying groceries; climbing several 
flights of stairs; climbing one flight of stairs; bending, kneeling, or stooping; walking more than 
a mile; walking several blocks; walking one block; bathing or dressing (Table 3).  Each item was 
scored on a 0 to 100 range as follows: 100= not limited at all; 50= limited a little; and 0= limited 
a lot, based on the RAND scoring method.252  A mean of the 10 activities was then calculated to 
determine an overall score for the PF 10 ranging from 0 to 100 with a score of 100 indicating 
that a participant’s health did not limit his ability to complete physical activity.  Thus, a lower 
score indicates lower physical function. The first visit at which a participant has a PF score was 
defined as the baseline visit.  Given the strong correlation between an individual’s baseline 
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physical function score and his overall mean physical function score (r=0.82; p <0.0001), the 
baseline score was used in the analysis.   
 
2.3.4 Covariates 
Covariates of interest included age, race, HIV status, AIDS status, body mass index (BMI), and 
CD4 count and were obtained for all individuals from the baseline visit, defined as the visit at 
which a participant had an initial recording of the covariate during visit 31-visit 44.  These 
covariates were chosen because of their association with physical function and/or diabetes 
development253, 254. 
2.3.5 Statistical Methods 
SAS Version 9.1 was used for all statistical analysis.  The Fisher exact, Wilcoxon, and Kruskal-
Wallis nonparametric tests, as appropriate, were used to test for differences in proportions and 
distributions for both HIV serostatus and diabetes status groups.  Differences in physical function 
scores between glycemic groups (normal, pre-diabetes, and diabetes) were assessed using the 
Kruskal-Wallis Test.  These differences were also tested after stratification by HIV status as well 
as AIDS status.  Chi-square and Wilcoxon Rank Sum tests were used to assess associations 
between physical function scores for insulin levels and HOMA scores stratified by HIV 
serostatus.  Statistical significance was determined using two tailed tests with an alpha of 0.05. 
Univariate logistic regression analysis was performed to assess unadjusted associations between 
predictors and the binary outcome of interest, diabetes status.  We compared individuals with 
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diabetes to those with normoglycemia; individuals with pre-diabetes were excluded from the 
regression analysis thus reducing the sample size to 289 for this analysis only.  Multivariate 
logistic regression using a forward stepwise methodology for the addition of significant variables 
was used to assess the association between DM and baseline physical function score as well as to 
assess the association between IR and baseline physical function using a  p-value cut-off of 
<0.05 for inclusion in the model.  Predictors that were not significant in the multivariate analysis 
were not retained in the model regardless of statistical significance in univariate analysis.  
Regression analysis was also completed separately for HIV-negative and HIV-positive men to 
determine whether or not risk factors for elevated glucose and insulin resistance differed by HIV 
status.   
2.4 RESULTS 
The baseline characteristics of the 658 men stratified by glucose level and HIV serostatus are 
displayed in Table 4.  Seventy five percent of men were white. Overall, HIV negative men were 
older than HIV-positive men.  BMIs were significantly lower among HIV-positive in those with 
pre-diabetes and diabetes and among HIV-positive men with normoglycemia although the 
difference was not significant.  CD4 counts, as expected, were significantly lower in HIV-
positive men independent of diabetes status. Fasting insulin levels and HOMA scores were 
higher among the HIV-positive men across all glucose levels, although the differences were not 
statistically significant.  
Men with diabetes mellitus were older and had higher BMIs than men with 
normoglycemia and pre-diabetes.  A higher proportion of black men as well as HIV-positive men 
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with AIDS had fasting glucose levels consistent with diabetes.  In both HIV-positive and HIV 
negative men, IR and hyperinsulinemia increased progressively from those with normoglycemia 
to pre-diabetes and diabetes. 
Table 5 shows the individual mean self-reported physical function scores by diabetes 
status for thirteen six-month periods commencing April 1, 1999. Men with diabetes consistently 
had the lowest physical function scores while men with normoglycemia and pre-diabetes had 
relatively similar scores.  Significant differences between the three glucose levels occurred in 
later visits likely due to larger sample sizes (accounting for a second MACS recruitment). 
In both HIV-negative and HIV-positive men, baseline physical function scores were 
lower for men with hyperinsulinemia.   In addition, physical function scores were lower in HIV-
positive men compared to HIV-negative men for both insulin levels.  Similarly, baseline physical 
function scores were lower in men with HOMA levels > 3 in both HIV negative and HIV-
positive men.  Physical function scores were lower for both HOMA levels in HIV-positive men 
as compared to men without HIV (Tables 6 and 7). 
The relationship between DM status and baseline physical function by HIV serostatus 
and men with AIDS is illustrated in Figure 1.  Overall, the best physical function scores were 
observed among HIV-negative men with normoglycemia.  HIV-negative males had better 
physical function scores compared with HIV-positive males in each of glucose levels. Among 
HIV-negative males, mean physical function scores decreased as glucose levels increased 
(p<0.0001).  The men with normoglycemia had the highest physical function scores while the 
men the diabetes had the lowest scores in HIV-negative men, HIV-positive men and men with 
AIDS; however significant differences were only observed in the HIV-negative group, likely due 
to the small number of men with HIV-infection and AIDS.  In addition, the mean physical 
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function scores for men with AIDS were lower than both the HIV negative men and the HIV-
positive men in all three of the glucose levels.  Men with both diabetes and AIDS had the lowest 
mean physical function score among all groups. 
In the univariate analysis (Table 8), lower physical function score (OR 1.9 per 25 unit 
decrease, p <0.0001); higher BMI (OR=1.6 per 5 units, p=0.0012) and older age (OR 1.5 per 5 
years, p<0.0001) were found to be independently associated with diabetes.  Baseline CD4 
counts, AIDS status, HIV status and race were not significantly associated with diabetes in the 
univariate analysis.  However, in the multivariate analysis, lower physical function score 
(OR=1.5 per 25 unit decrease, p=0.02), older age (OR = 1.5 per 5 years, p<0.0001), and black 
race (OR=2.8, p=0.002) were found to be significantly associated with diabetes.  BMI and AIDS 
were not found to be significant at p=0.05 and thus were not included in the final model.  
However, given the known relationship between BMI and DM in HIV-negative populations255 a 
sensitivity analysis was completed to determine if results changed with BMI forced into the 
model (data not shown).  All three variables, physical function, age and race, remained 
significant with BMI in the model, suggesting that BMI did not influence DM in this study 
therefore BMI was removed from the model for parsimony.  Given the observation that physical 
function scores were slightly lower among HIV-positive men compared with negative men, an 
interaction between HIV serostatus and mean physical function scores was tested in both 
univariate and multivariate analysis. This interaction was not statistically significant (p=0.9; data 
not shown).  After stratification by HIV infection, age and race remained significantly associated 
with DM status regardless of HIV status, however BMI was associated with diabetes in the HIV-
negative men.  Physical function was not associated with diabetes in either HIV group after 
stratification. 
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Table 8 also shows univariate and multivariate associations with IR.  In the univariate 
analysis, physical function score (OR=2.4 per 25 unit decrease, p<0.0001); older age (OR=1.3 
per 5 years, p<0.0001); higher BMI (OR=2.6 per 5 units, p<0.0001) and HIV infection (OR=1.5, 
p=0.01); and black race (OR=2.0, p=0.006) were associated with IR.  However in the 
multivariate analysis, the HIV/physical function interaction became significant (OR 2.1, 
p=0.0003) while older age (OR=1.3 per 5 years, p<0.0001); higher BMI (OR=2.8 per 5 units, 
p<0.0001); HIV infection (OR=11.3, p=0.0002); and black race (OR=2.0, p=0.002) remained 
associated with IR.  Neither CD4 count nor AIDS status were associated with IR in either 
univariate or multivariate analysis.  After stratification by HIV infection, BMI, age, and race 
were associated with IR in HIV-negative men and age, BMI, and physical function were 
associated with IR in HIV-positive men.   
2.5 DISCUSSION 
Our data suggest that self-reported low physical function as a surrogate for low physical activity 
is associated with DM, independent of HIV status.  After adjustment for age and race, physical 
function remained significantly associated with DM such that for every 25 unit decrease in 
physical function score, the odds of having DM increased by 50% (p<0.05). This result is 
strengthened by our observation that insulin levels and insulin resistance were also associated 
with lower physical function scores especially among HIV-positive men (Tables 6 and 7).  While 
the main effect of physical function score was not associated with IR in multivariate analysis, the 
significance of the physical function/HIV status interaction deserves attention.  This indicates 
that the effect of low physical function on insulin resistance depended upon HIV status such that 
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the odds of having insulin resistance were greater for men with both low physical function scores 
and HIV infection (OR 2.1, p=0.0003). Alternatively, the association between HIV infection and 
IR, but not DM, may simply indicate that IR precedes DM and we had greater statistical power 
to detect this.  While this association needs to be replicated in other cohort studies, it is important 
to encourage physical activity among individuals with HIV. Using previously published studies 
that support the use of physical function as a surrogate for physical activity15-20, it is plausible to 
suggest that low physical activity levels may be associated with the onset of insulin resistance 
and DM in HIV-positive men. 
In addition, our finding that physical function scores were lowest among persons with 
AIDS provides important information regarding DM in our population despite the lack of 
statistical significance.  As shown in Figure 1, persons with AIDS contributed strongly to lower 
physical function scores among those with diabetes.  This association is highly plausible as 
persons with late stage HIV infection and AIDS have likely experienced multiple events which 
contributed to lower physical function over a long history of HIV infection.  It is possible that the 
lack of statistical significance was due to the limited sample of persons with AIDS (n=28).  
Studies with larger samples of individuals with AIDS should be completed to further clarify the 
contribution of AIDS to the complex relationship between physical function and DM in the HIV 
positive population.   
BMI was not found to be associated with diabetes mellitus in the multivariate analysis in 
this study.  While higher BMI is a known risk factor for DM, BMIs among HIV-positive 
individuals tend to be lower with subsequent loss of subcutaneous adipose tissue (without 
increases in visceral adipose tissue) compared with the HIV-negative population 256-258.   This 
was true in our study in which 40.3% of HIV negative men were overweight compared with 
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36.5% in the HIV-positive group.  The HIV-negative men also had higher frequencies of obesity 
compared to the HIV-positive men.  Therefore, the lack of association between BMI and DM 
after adjustment for HIV status and the other covariates is not surprising.  Our result was 
strengthened by the observation that BMI was associated with DM in the HIV-negative men but 
not in the HIV-positive men.  This seemingly contradictory finding highlights the difficulty in 
assessing the role of BMI as a risk factor for most metabolic disturbances common to those with 
HIV infection.  We were unable to measure visceral fat as a component of BMI in this study and 
therefore our inferences are limited to BMI. 
Our findings using physical function as a surrogate for physical activity support a 
previous observation by Howard et al that physical activity may be independently associated 
with diabetes mellitus in HIV-positive women108.  However, this result was not replicated in their 
similarly designed study in a sample of HIV-positive men109.  Likewise, Danoff et al120 failed to 
find an association with physical activity and diabetes among HIV-positive women.  The current 
study differs from these three previous studies as it is composed primarily of Caucasians (75%) 
rather than African American and Hispanic cohorts.  Compared to the Howard men’s study109, 
the HIV-positive men in our cohort have a younger median age (42 years) but similar BMI 
compositions (45% with normal BMI). The differing demographics between studies may 
partially explain the discrepancy between our findings and those in the Howard study.  Because 
both older age and African American race are known risk factors for diabetes mellitus253, our 
cohort of younger, Caucasian men may allow for an increased association of low physical 
function and diabetes mellitus compared to the older, African American cohort in the Howard 
study.  However, comparisons between our study and the Howard studies are difficult given our 
use of physical function data as a surrogate for physical activity level.   
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The present study had several limitations.  First, given the design of this study, a temporal 
relationship between impaired physical function and diabetes development was not determined.  
Therefore, it is possible that the lower physical function scores are a result of the diabetes, rather 
than a precursor to its onset. Recent literature implies that the presence of diabetes may 
independently contribute to impaired exercise capacity188.  Left ventricular dysfunction 188, 
aging, female sex, poor diabetes control, reduced heart rate recovery, obesity189, 190, race190, 
impaired femoral arterial blood flow191, and impaired exercise stroke volumes192, as well as 
microvascular diabetic complications including neuropathy and retinopathy193 may be associated 
with impaired exercise capacity in type 2 diabetes.  Regensteiner et al, also observed a reduced 
rate of increase in oxygen consumption during treadmill testing of healthy patients with non-
insulin dependent diabetes, indicating that oxygen delivery limitations may lead to impaired 
exercise performance194. However, given the noted correlation between the baseline and overall 
mean physical function scores in our study, it is reasonable to suggest that physical function 
scores did not drastically decrease following the onset of diabetes.  It is also important to note 
that other factors such as ongoing substance abuse, depression, and chronic physical and mental 
health issues may also affect physical function.  Future research using larger cohort studies to 
establish incident diabetes cases are necessary to establish a temporal association and to verify 
the results of this analysis while simultaneously assessing the contribution of additional factors 
to low physical activity.  Secondly, the physical function measure used in this study does not 
objectively measure physical activity but rather serves as a surrogate by assessing how a person’s 
health status limits his ability to complete physical function tasks.  As previously discussed, 
numerous studies in HIV-negative populations established that physical activity levels are 
correlated with physical function performance.  Brach et al observed a correlation between 
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pedometer readings as a measure of physical activity with the Functional Status Questionnaire 
(r=0.34); the Physical Performance Test (r=0.41); and gait speed (r=0.52)15.  Both cross-sectional 
and prospective studies suggest that low physical activity levels are an independent predictor of 
both measured and self-reported low physical function15-20.  A recent study in 8,702 U.S. and 
1,507 British middle-aged adults (aged 50 to 69), found that physical activity was protective 
against impaired incident physical function (self-report and measured) independent of BMI.205  
Participants who reported > 3 days of activity per week had a lower incidence of physical 
impairment than individuals who reported less activity in each BMI category (recommended 
weight, overweight, obese). Hillsdon et al also show that regular physical activity (defined as 2.5 
hours per week of moderate PA or > 1 hour of vigorous activity per week) is associated with 
high self-reported physical function (OR 1.6, 95% CI 1.3-1.98 adjusted for age, gender, chronic 
illness, baseline PF, BMI, smoking, and SES) in a cohort of 6,398 middle aged men and women 
(aged 39 to 63 years)18.  Despite the lack of objectively measured physical activity, these studies 
are important because they extend the protective effect of physical activity to slightly younger 
populations. While similar studies have not yet been conducted in HIV-positive cohorts, 
Roubenoff and Wilson, reported an increase in physical function status in patients with HIV 
wasting who completed a resistance training program21.  Therefore, the use of physical function 
as a surrogate for physical activity, although not ideal, was justified.  Studies that objectively 
measure physical activity levels will need to be completed to verify and strengthen our results.  
Finally, this study was unable to assess the impact of antiretroviral therapy on diabetes mellitus 
as over 90% of the HIV-positive men utilized HAART at some point during the study period and 
there was little variation in the duration of HAART usage.  However, this inability to assess the 
association of HAART and DM does not detract from our inference that impaired physical 
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function is associated with DM given that physical function scores were significantly lower in 
the both the HIV-negative and HIV-positive men with diabetes. 
2.6  CONCLUSIONS 
Despite evidence that physical inactivity may play a role in the development of DM among HIV-
negative individuals63, 71, 246, the majority of studies of DM and IR in HIV-positive populations 
have not accounted for physical activity, potentially over-estimating the role of anti-retroviral 
therapy as a cause of diabetes in this population10, 123, 259.  This study found that self-reported low 
physical function as a surrogate for physical activity was associated with DM and IR in both 
HIV-positive and HIV-negative men.  Given these results, future research using objective 
physical activity measures is warranted to further understand the contribution of low physical 
activity to DM and IR among HIV-positive populations.  Ongoing HIV cohort studies addressing 
the issues of glucose metabolism in HIV-positive populations should address the role of physical 
activity.  
2.7  SUMMARY POINTS 
o HIV-positive men had lower physical function scores than HIV-negative men. 
o HIV-positive men had lower physical function scores than HIV-negative men regardless 
of insulin level and HOMA score.  
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o Men with diabetes had consistently lower mean physical function scores than both the 
pre-diabetic men and the normoglycemic men.  
o Baseline physical function scores were lower for men with hyperinsulinemia and men 
with HOMA levels > 3 among HIV-negative and HIV-positive participants.   
o Men with both diabetes and AIDS had the lowest mean physical function score among all 
men. 
o In multivariate analysis, lower physical function score (OR=1.5 per 25 unit decrease, 
p=0.02), older age (OR = 1.5 per 5 years, p<0.0001), and black race (OR=2.8, p=0.002) 
were found to be significantly associated with diabetes.   
o In multivariate analysis, older age (OR=1.3 per 5 years, p<0.0001); higher BMI (OR=2.8 
per 5 units, p<0.0001); HIV infection (OR=11.3, p=0.01); black race (OR=2.0, p=0.004); 
and the interaction between HIV and physical function (OR=2.1, p=0.0003) were 
associated with IR. 
o This study concluded that low physical function (as a surrogate for physical activity) was 
associated with DM and IR in both HIV-positive and HIV-negative men.   
o Future research using objective physical activity measures is warranted to further 
understand the contribution of low physical activity to DM and IR among HIV-positive 
populations.  
2.8  FUTURE PERSPECTIVE 
Over the next decade, clinical trials among HIV-positive populations similar to those 
completed in HIV-negative populations would be required in order to establish a casual 
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association between low physical activity and the onset of DM and IR.  This will take time.  
At present, researchers and clinicians alike are encouraged to consider the potential for a 
similar benefit to HIV-positive individuals as demonstrated in the general population.  As 
this relationship becomes more clearly recognized, increased physical activity will become 
an integral part of diabetes prevention and management in HIV-positive individuals.   
2.9  TABLES 
  
Table 3. Physical Function 10 (PF 10) questions from the Medical Outcomes Study (MOS) 
36-Item Short Form Health Survey (SF 36) 
“The following items are about activities 
you might do during a typical day.  Does 
your health now limit you in these 










Vigorous activities, such as running, lifting 
heavy objects, participating in strenuous 
sports 
   
Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling, or 
playing golf 
   
Lifting or carrying groceries    
Climbing several flights of stairs    
Climbing one flight of stairs    
Bending, kneeling, or stooping    
Walking more than a mile    
Walking several blocks    
Walking one block    






Table 4. Baseline demographics by HIV serostatus and glucose levels 






















 n =36 
 
Age (median) 














Race n (%)       0.05 
    White 95 (76.6) 65 (83.3) 176 (84.2) 133 (83.1) 34 (69.4) 26 (72.2)  
    Black 27 (21.8) 13 (16.7) 30 (14.4) 24 (15.0) 15 (30.6) 8 (22.2)  
    Other 2 (1.6) 0 (0) 3 (1.4) 3 (1.9) 0 (0) 2 (5.6)  













AIDS n (%) N/A 10  (4.9) N/A 11 (3) N/A 8 (9.30)  













Insulin n (%)       <0.0001 
   < 15 µU/ml 92 (73.6) 50 (64.1) 91 (43.5) 57 (35.6) 8 (16) 1 (2.78)  
   > 15 µU/ml 33 (26.4) 28 (35.9) 118 (56.5) 103 (64.4) 42 (84) 35 (97.2)  
HOMA-IR, 
median µU/ml x 
mmol/L 
2.2 2.4 3.0 3.3 6.5 6.7 <0.0001 
Wilcoxon Rank Sum for continuous variables and Fisher’s Exact for categorical variables for serostatus 
comparisons 
Kruskal-Wallis for continuous variables or Fisher’s Exact for categorical variables for overall glucose comparisons 
BMI: Body mass index; HOMA-IR: homeostasis model assessment insulin resistance  
* p <0.05 between HIV negative and HIV-positive men with normoglycemia 
** p <0.05 between HIV negative and HIV-positive with pre-diabetes 
*** p <0.05 between HIV negative and HIV-positive with diabetes 




Table 5. Mean cross-sectional Physical Function 10 scores from the Short Form-36 by 
diabetes status at each visit date (HIV-negative and HIV-positive men) 
Visit Date Normo-glycemic Pre-Diabetes Diabetes p-value 
4/1/1999-9/30/1999  (n=27) 90.7 97.3 89.0 0.89 
10/1/1999-3/31/2000 (n=114) 85.5 89.1 86.1 0.96 
4/1/2000-9/30/2000 (n=106) 96.9 88.9 78.8 0.23 
10/1/2000-3/31/2001 (n=119) 89.0 92.4 84.4 0.42 
4/1/2001-9/30/2001 (n=101) 90.0 91.3 86.3 0.79 
10/1/2001- 3/31/2002 (n=190) 86.9 91.4 89.5 0.35 
4/1/2002- 9/30/2002 (n=202) 89.6 90.6 82.8 0.01* 
10/1/2002- 3/31/2003 (n=245) 93.5 91.1 87.6 0.09 
4/1/2003- 9/30/2003 (n=340) 91.4 90.7 77.9 <0.0001* 
10/1/2003- 3/31/2004 (n=337) 93.6 89.4 79.0 0.008* 
4/1/2004- 9/30/2004 (n=370) 90.7 90.8 80.8 0.009* 
10/1/2004- 3/31/2005 (n=375) 91.5 88.6 78.2 0.003* 
10/1/2005- 3/31/2006 (n=388) 92.2 88.1 77.5 <0.0001* 
Kruskal-Wallis Test for all comparisons 
*indicates significant at p <0.05 
 
 
Table 6.  Baseline characteristics of study populations by HIV serostatus and insulin levels 
 HIV-negative (n=366) HIV-positive  (n=239) 
 Insulin 
  < 15 µU/ml 
Insulin 
 >15 µU/ml 
P-value Insulin 
  < 15 µU/ml 
Insulin 
 >15 µU/ml 
P-value 
 Physical function 













Age (median) 42.4 50.4 <0.0001 41.2 42.7 0.05 
BMI (median) 25.5 27.5 <0.0001 25.4 24.3 0.13 
Race, n (%)   0.02   0.15 
    White 221 (59.6) 77 (20.8)  136 (54) 61(27)  
    Black 39 (10.5) 29 (7.8)  22 (8.7) 20 (8.3)  






Table 7. Baseline physical function score by HIV serostatus and HOMA score 
Note: Wilcoxon Rank Sum for continuous variables and Chi square test for categorical variables.  HOMA-IR: 




Table 8. Multivariate logistic regression analysis of baseline factors associated with 
diabetes and insulin resistance among HIV-positive and -negative men 













 Diabetes (n=262) Insulin resistance (HOMA-IR) (n=239) 
Physical 
function score 
(Per 25 unit 
decrease) 
1.9 <.0001 1.5 0.02 2.4+ <.0001 1.2 0.26 
Age  
(Per 5 year 
increase)  
1.5 <.0001 1.5 <.0001 1.3 <.0001 1.3 <0.0001 
BMI 
(Per 5 unit 
increase) 
1.6* 0.0012   2.6 <.0001 2.8 <0.0001 
AIDS Statusa 2.0* 0.2   1.5** 0.3   
HIV Statusb 1.2* 0.6   1.5 0.01 11.3 0.01 
Racec 1.6 0.1 2.8 0.002 2.0 0.006 2.0 0.004 




      2.1 0.0003 
 HIV-negative (n=366) HIV-positive(n=239) 
  HOMA-IR  
< 3 µU/ml x 
mmol/L 
HOMA-IR  
> 3µU/ml x 
mmol/L 
P-value HOMA-IR  
< 3 µU/ml x 
mmol/L 
HOMA-IR  





      











































































HIV-negative*    HIV-infected AIDS  
N=378 N=259 N=28
Figure 1.  Mean baseline physical function scores by diabetes status for HIV-negative men, HIV-positive men, 
and men with AIDS (Mean + 1 standard deviation)  
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Aims:  To evaluate relationships between physical function, incident diabetes mellitus (DM) and 
insulin resistance (IR) among HIV-infected and uninfected men.   
Methods: We analyzed data from 1790 HIV-infected and uninfected men in the Multicenter 
AIDS Cohort Study.  DM was defined in two ways using less stringent and more stringent 
criteria.  The Physical Functioning Ten Scale from the Short Form-36 Health Survey measured 
baseline physical function.  Cox regression assessed associations between physical function and 
DM and IR. 
Results:  73 men developed diabetes using the more stringent definition compared to 238 using 
the less stringent definition. Cumulative DM incidence was highest among HIV-uninfected and 
HIV-infected men with low physical function.  Physical function was a risk factor for DM in 
HIV-uninfected men and remained so after controlling for BMI, DM family history, and race 
using both the more stringent (hazard ratio (HR) 1.31; 95% CI 1.02-1.66) and less stringent (HR 
1.29; 95% CI 1.11-1.50) diabetes definitions.  Among HIV-infected men, physical function was 
an independent risk factor for DM using the less stringent diabetes definition.   
Conclusions:  This study supports our previous findings that low physical function is an 
important risk factor for DM in the MACS cohort. 
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3.2 INTRODUCTION 
The introduction of highly active antiretroviral therapy (HAART) dramatically changed the 
course of HIV infection99. Individuals living with HIV infection have a longer life expectancy, 
albeit faced with co-morbidities common in the general population that may be accelerated due 
to infection with HIV260. Diabetes mellitus (DM) and insulin resistance (IR) are two such 
conditions.  Current studies document a high prevalence and incidence of Type 2 DM in HIV-
infected men.  The Multicenter AIDS Cohort Study (MACS) reported a 14% prevalence of 
diabetes mellitus (DM) among HIV-infected men compared to 5% among HIV-uninfected men 
and an incidence rate of 4.7 cases per 100 person-years compared with an incidence rate of 1.4 
cases per 100 person years among HIV negative men106.  There is also a greater prevalence of 
insulin resistance reported in HIV-infected patients with lipodystrophy (35%) compared to 
matched controls without HIV (5%)128.  This trend has also been noted in HIV-infected patients 
without lipodystrophy (5.6% IR prevalence) when compared to controls (3.3% IR prevalence)128.  
To date, the etiology of DM and IR in HIV infection remains unclear.  Traditional risk 
factors such as advancing age10, 109 and higher BMI10, 109 have consistently been reported and 
HIV specific risk factors such as HAART use100, 110 are thought to play a role.   
Physical activity is an accepted intervention for the prevention of DM in the general 
population42-50 and low physical activity helps to predict the incidence of new-onset DM48, 261.  
However, physical activity’s role as a contributing factor to the incidence and prevention of DM 
has not been described in most studies of HIV-infected populations10-14.  
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We previously demonstrated that low physical function was associated with DM and IR 
in a cohort of HIV-infected and uninfected men from the Pittsburgh component of the MACS262.  
This result was strengthened by our observation that insulin levels and markers of insulin 
resistance were also associated with lower physical function scores among HIV-infected men.   
However, sample size did not permit the exclusion of prevalent diabetes and a temporal 
relationship could not be established.  In addition, we were unable to assess the impact of 
antiretroviral therapy on DM incidence.  
Physical activity and physical function are related, yet, distinct.  Physical activity is 
defined as any voluntary movement produced by the skeletal muscles that results in increased 
energy expenditure201, whereas physical function is defined as one’s ability to carry out various 
activities that require physical capability, ranging from self-care to more vigorous activities that 
require increasing degrees of mobility, strength, or endurance202.  Despite these differences, 
numerous studies in HIV-uninfected populations have established that physical activity levels are 
correlated with physical function15-20.  Among HIV-infected persons, resistance training has been 
shown to improve self-reported physical function in patients with HIV wasting21.   Therefore, 
physical function is likely to reflect physical activity. 
The current study addresses important limitations of our prior study262 by using incident 
diabetes cases from the MACS cohort to assess the independent contribution of physical function 
to the onset of DM and IR in HIV-infected and uninfected men.  The effect of highly active 
antiretroviral therapy (HAART) on this relationship was assessed.  Finally, we compared the 
incidence rates of diabetes among HIV-infected and uninfected men with low physical function 




3.3.1 Study Participants 
All participants were from the Multicenter AIDS Cohort Study (MACS).  The MACS is an 
ongoing NIH-supported (Baltimore, MD; Chicago, IL; Los Angeles, CA; and Pittsburgh, PA) 
prospective cohort study of the natural history of HIV infection.  It was designed to gather 
information on the epidemiology, virology, immunology, and pathogenesis of HIV.  Homosexual 
and bisexual men aged > 18 years without AIDS were recruited from local communities in three 
recruitment cycles (April 1984-March 1985; April 1987-September 1991; October 2001-August 
2003).  Briefly, the MACS follows a 6-month visit schedule and involves detailed data collection 
regarding medical history, physical examination results, and specimen collection. Institutional 
review boards at each site approved the protocol, and each participant provided informed 
consent.  Further detail can be found elsewhere 247, 263.   
Our analysis includes data collected after implementation of the MACS Metabolic Study 
in April 1999 when serum samples (> 8 hours fasting) were added to measure glucose and 
insulin levels.  The first visit at which a participant had such testing was defined as his baseline 
visit.  Of 2,800 eligible men, 193 (6.9%) had prevalent diabetes at baseline and were excluded. 
Prevalent diabetes was defined as a fasting glucose concentration of >126 mg/dL, self-reported 
DM, or use of an antidiabetic medication at baseline.  An additional 817 participants did not have 
any fasting serum samples and were excluded.  Therefore, the final sample includes 1790 men 
(1023 HIV-uninfected and 767 HIV-infected) without baseline diabetes. 
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3.3.2 End Point Ascertainment-Diabetes Mellitus and Insulin Resistance 
Diabetes was defined at each bi-annual visit from April 1, 1999 through April 2, 2008.  The date 
of incident DM was defined as the mid-point between the last visit with a fasting glucose 
concentration <126 mg/dL and the date of the first visit with a fasting glucose concentration of 
>126 mg/dL.  Incident DM was defined in two ways.  The first definition, consistent with our 
previous work3, was a single fasting glucose of >126 mg/dL, self-reported DM, or use of an 
antidiabetic medication.   The second, more stringent definition, required two consecutive 6-
month visits with a fasting glucose of > 126 mg/dL, 1 visit with a glucose of > 126 mg/dL and 
self-reported initiation of antidiabetics medication or self-reported DM.   
Insulin concentrations were also obtained from fasting serum samples.  IR was estimated 
using the homeostasis model assessment (HOMA): (fasting insulin [(µU/ml] x fasting glucose 
[mmol/L)]/22.5.248  IR was defined by the highest HOMA quintile (>4.3 µU/ml x mmol/L).  Men 
with prevalent IR were excluded from incident IR analysis. 
3.3.3 Exposure-Self-reported Physical Function 
The Physical Functioning Ten Scale from the Medical Outcomes Study Short Form-36 Health 
Survey served as the physical function measure.  The SF-36 is one of the most widely used 
Health Related Quality of Life Instruments and consistently demonstrates high levels of 
reliability and validity (249-251).  In the MACS cohort, internal consistency estimates ranged from 
0.85 to 0.86 depending on the SF-36 scale used264.  
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This study includes data from PF 10 questionnaires administered at each bi-annual visit 
from April 1, 1999 through March 31, 2005 and then annually on even visit dates.  Participants 
were asked the following question regarding physical activities that might be done in a typical 
day: “Does your health now limit you in these activities?  If so, how much?”  Participants chose 
between “Yes, limited a lot”, “Yes, limited a little”, or “No, not limited at all” for vigorous 
activities (running, lifting heavy objects); moderate activities (vacuuming, golf); lifting or 
carrying groceries; climbing several flights of stairs; climbing one flight of stairs; bending, 
kneeling, or stooping; walking more than a mile; walking several blocks; walking one block; 
bathing or dressing.  Each item was scored on a 0 to 100 scale as follows: 100= not limited at all; 
50= limited a little; and 0= limited a lot, based on the RAND scoring method252.  A mean of the 
10 activities was calculated to determine an overall score ranging from 0 to 100 with a score of 
100 indicating that a participant’s health did not limit his ability to complete physical activity.  A 
lower score indicated lower physical function.  For use in Kaplan-Meier plots, baseline physical 
function scores were categorized as high physical function (> than 80) and low physical function 
(< to 80).  A score of 80 was chosen based on the lowest quintile of physical function in the 
current study population. Baseline physical function score was used in multivariate models as a 
continuous variable.  
3.3.4 Assessment of Exposure to Antiretroviral Therapy 
Each visit includes detailed questions regarding the use of specific antiretroviral therapies.  The 
definition of HAART followed the DHHS/Kaiser Panel Guidelines and has been described 
elsewhere265, 266. 
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Men were classified into the following 3 groups: 1) HIV-uninfected; 2) HIV-infected not 
using HAART; and 3) HIV-infected using HAART.  The “HIV-infected not using HAART 
group” combined men who were antiretroviral free (n=254), men using monotherapy (n=3), and 
men using less-than-HAART combination therapy (n=22) at the baseline visit.  This 
classification was chosen because of the small numbers of men using either monotherapy or less-
than-HAART combination therapy. 
3.3.5 Statistical Analysis 
SAS Version 9.2 was used for all statistical analyses.  Chi-square test and the Student’s t-test 
were used to test for differences in proportions and distributions between HIV serostatus groups 
and physical function groups.  Statistical significance was determined using two-tailed tests with 
an alpha of 0.05.  
In order to analyze incident DM/IR, person-time for each participant was calculated from 
the date of the baseline visit to the date of the onset of DM/IR or to the date of censoring at the 
last visit free of DM/IR (either due to loss to follow-up or to the study end date of April 2, 2008).  
Incidence rates per 100 person-years were calculated by dividing the number of DM/IR 
endpoints by person-years and multiplied by 100. 
The association between baseline physical function and incident DM was examined using 
unadjusted and adjusted hazard ratios (HR) from Cox proportional hazards regression models.  
Univariate Cox regression for each variable was used to determine the association between the 
variable of interest and incident DM.  Baseline physical function, used as a continuous variable, 
was forced into all models followed by the addition of each significant variable from the 
univariate analyses, from lowest to highest p-value.  Models were run separately for all men 
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combined, HIV-uninfected men and HIV-infected men.  An identical model-building strategy 
was used to examine the association between physical function and incident IR.  The 
proportional hazard assumption was met based on visual inspection of Kaplan-Meier survival 
curves. 
3.4 RESULTS 
The baseline characteristics of the 1790 men, of whom 43% were HIV-infected, are displayed in 
Table 9.  The mean age of the study population was 43.1 years, 58.2% were white, 31.1% had a 
family history of diabetes and 66% had a history of smoking.  The mean BMI was 25.9 kg/m2 
and the mean physical function score was 86.0 (SD 22.1).   
The HIV-infected men were younger, had a lower mean BMI, and lower CD4 counts.  
The mean baseline physical function score was significantly lower (p<0.001) in HIV-infected 
men (mean 83.0; SD 23.3) compared with HIV-uninfected men (mean 88.2, SD 20.8).  A greater 
proportion of HIV-infected men was non-white and had a history of smoking.  Mean glucose 
levels and family history of DM did not differ between HIV serostatus groups; however mean 
insulin (p=0.0007) and HOMA levels (p=0.0006) were significantly higher in HIV-infected men.  
Table 10 compares men with high and low physical function, stratified by HIV 
serostatus.  Characteristics tended to differ more in HIV-uninfected men compared with the HIV-
infected men.  Among the HIV-uninfected men, those with low physical function were older and 
had higher insulin and HOMA levels.  In addition, a greater proportion of men with low physical 
function were non-white while a higher proportion of men had a history of smoking.  BMI, 
fasting glucose concentrations, and family history of DM did not differ.   
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In the HIV-infected men, race, CD4 count, and proportion with AIDS differed by 
physical function level.  A greater proportion of men with low physical function were non-white.  
HIV-infected men with low physical function had lower CD4 counts and a higher proportion had 
AIDS.  None of the other characteristics differed significantly between men with high and low 
physical function in the HIV-infected group. 
Incident DM varied substantially depending on the diabetes definition used.  Of the 1790 
men, 73 developed diabetes (41 HIV-uninfected and 32 HIV-infected) using the more stringent 
definition.  Forty-three incident cases were due to two consecutive glucose concentrations of 
>126 mg/dl, or 1 elevated glucose (> 126 mg/dl) with the initiation of antidiabetic medications, 
22 were due to a self-reported diagnosis of DM and 8 were due only to self-reported use of 
antidiabetic medications. When using the less stringent definition, 238 (126 HIV-uninfected and 
112 HIV-infected) incident cases of diabetes were observed.  One hundred ninety two of these 
were due to a single elevated fasting glucose (> 126 mg/dl), 27 were due to a self-reported 
diagnosis of DM and 19 were due only to self-reported use of antidiabetic medications.  A total 
of 520 (30%) were lost to follow-up. The median follow-up was 5.0 years.  
 The incidence rate for DM among all men was 0.943 per 100 person-years (PY) using 
the more stringent definition and 3.24 per 100 PY using the less stringent definition.  Among 
HIV-uninfected men the rate was 0.896 per 100 PY using the more stringent definition and 2.89 
per 100 PY with the less stringent definition.  Finally, among HIV-infected men, use of the more 
stringent definition yielded a rate of 1.04 per 100 PY compared with 3.75 per 100 PY using the 
less stringent definition.  Similarly, the DM definition used strongly influenced the incidence 
rates for HIV-infected men based on HAART status.  HIV-infected men using HAART had an 
incidence rate range of 1.0 per 100 PY using the more stringent definition compared to 3.97 per 
86 
100 PY using the less stringent definition.  The HIV-infected men not using HAART had a rate 
of 1.1 per 100 PY with the more stringent definition and 2.48 per 100 PY. 
Figure 2 presents the percentage of men free of DM stratified by HIV status and physical 
function for both definitions of DM.   The cumulative incidence of DM was higher (smaller 
percentage of participants free of diabetes) in all four groups when the less stringent definition 
was used.  Regardless of definition used, the cumulative DM incidence was highest among HIV-
uninfected men with low physical function and next highest in HIV-infected men with low 
physical function.  The log-rank test across the 4 strata was not significant (p=.15) when using 
the more stringent definition.  When the less stringent DM definition was used, the 4 strata differ 
significantly from one another (p<0.001).  
In the univariate analysis (data not shown), lower physical function score (HR 1.34 per 
20 point decrease, p < 0.001); higher BMI (HR=1.13, p < 0.001); older age (HR 1.17 per 5 year 
increase, p=0.006); non-white race (HR 1.77, p=0.02); and family history of DM (HR 1.68, 
p=0.004) were found to be individually associated with diabetes when using the more stringent 
definition.  Baseline CD4 cell counts and HIV serostatus were not significantly associated with 
diabetes in the univariate analysis.  The same covariates were found to be significant when using 
the less stringent definition.  Among HIV-uninfected men, lower physical function, BMI and 
family history of DM were associated with DM when the more stringent definition was used.  
When using the less stringent definition age, race, and CD4 cell count were also associated with 
DM.  Among HIV-infected men only age and BMI were significant risk factors.  Neither 
physical function nor HAART use was significantly associated with DM in HIV-infected men 
using the more stringent definition; however using the less stringent definition, physical function, 
race, and family history of DM were significantly associated with DM. 
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To determine the independent effect of physical function on DM after adjustment for 
covariates, a series of multivariate Cox models were used for both diabetes definitions (Table 
11).  When using the more stringent definition, the physical function HR was somewhat 
diminished after adjustment for BMI, family history of DM and age but remained a significant 
risk factor for incident DM (HR 1.24; 95% CI 1.04-1.49) in all men.  The effect of physical 
function was no longer significant with the addition of race into the model (HR 1.14; 95% CI 
0.94-1.38).  While the use of the less stringent definition had little effect on the HR for DM when 
compared with the more stringent definition, it is important to note that physical function 
remained significant after adjustment for all covariates, including the addition of race to the 
model (HR 1.21, 95% CI 1.08-1.35).  The first order interaction between HIV and physical 
function was not significant using either definition. 
For HIV-uninfected men, adjustment for BMI, family history of DM, and race had little 
effect on the independent effect of physical function on incident DM (HR 1.31; 95% CI 1.02-
1.66) using the more stringent definition.  After the addition of age, physical function was no 
longer a significant risk factor; however the HR was only slightly attenuated (HR 1.24; 95% CI 
0.96-1.60).  Use of the less stringent definition did not change the HR for DM among HIV-
uninfected men, yet physical function remained significantly associated with DM in the model 
with all covariates entered (HR 1.20, 95% CI 1.02-1.41).    
The choice of DM definition had the greatest impact in the HIV-infected men.  Using the 
more stringent definition, physical function was not an independent risk factor for incident DM 
and adjustment for BMI, age, and race had little effect on the HR.  When the less stringent 
definition was used, the HR ratio increased and physical function was independently associated 
with DM even after adjustment for BMI and age (HR 1.23, 95% CI 1.06-1.44).  Although the 
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addition of race to the model did not change the HR only borderline significance was achieved 
(HR 1.16, 95% CI 1.00-1.38). 
Lower physical function (HR 1.15, p=0.002); higher BMI (HR 1.14, p<0.001), black race 
(HR 1.25, p=0.03); and HIV status (HR 1.24, p=0.005) were significantly associated with 
incident insulin resistance among all men in univariate analysis.  Among HIV-uninfected men, 
only physical function (HR 1.20, p=0.02) and BMI (HR 1.17, p<0.001), were associated with IR.  
As with the DM outcome, physical function was not an independent risk factor for IR in HIV-
infected men (HR 1.08, p=0.1) while older age (HR 1.20, p=0.01), higher BMI (HR 1.10, 
p=0.04) and HAART use (HR 1.7, p=0.05) were associated with incident IR.   
Adjustment for covariates only minimally decreased the HR for low physical function 
among all men with incident IR (Table 12).  Physical function was associated with insulin 
resistance in univariate analysis (HR 1.15; 95% CI 1.04-1.27) but was not significantly 
associated with IR after adjusting for covariates (although the HR remained unchanged).  
Similarly, among HIV-uninfected men, physical function was associated with IR in univariate 
analysis (HR 1.20; 95% CI 1.04-1.38) but the addition of BMI, CD4 count, and family history of 
DM attenuated the physical function HR (HR 1.01; 95% CI 0.84-1.22).  Finally, physical 
function was not an independent risk factor for incident IR in HIV-infected men (HR 1.08; 95% 
CI 0.94-1.25).   Adjustment for covariates had no effect on the HR.   
3.5 DISCUSSION 
Our finding that lower physical function is a risk factor for incident DM in a large cohort of 
HIV-uninfected and infected men is biologically plausible and supports our previous findings262.  
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Men with low physical function were more likely to develop diabetes than men with higher 
physical function, even after adjustment for risk factors such as BMI, family history of DM, and 
age.  We observed similar associations between physical function and DM in HIV-uninfected 
men but the association was weaker among HIV-infected men regardless of the DM definition 
used.  The current study expands our previous research262 by suggesting a temporal relationship 
between physical function and incident DM, as men with prevalent DM were excluded.  
Additionally, we assessed the effect of HAART use on incident DM and utilized a second, more 
stringent DM definition.  Given the strength of previous studies that support the strong 
correlation of physical function with physical activity15-20, our results are consistent with the 
notion that low physical activity is a risk factor for incident DM in HIV-uninfected and infected 
men.  
Although the majority of prior studies did not assess the role of physical function or 
physical activity as a contributing factor to DM among HIV-infected persons, our results support 
the  Howard et al108 and Gavrila et al186 studies, in which physical inactivity was associated with 
DM and IR in HIV-infected persons.  Our analysis is unique in that we used a prospective design 
with incident DM cases, in contrast to the cross-sectional designs used in prior studies.  We also 
included HIV-uninfected as well as HIV-infected men, allowing us to assess and control for 
HIV-infection.  Finally, we used a definition of DM consistent with ADA criteria22, while prior 
studies either used only self-reported DM or did not confirm glucose concentrations. 
HIV infection was not found to be a significant risk factor for DM in our study but was 
shown to be associated with incident IR in univariate analysis, consistent with our previous 
study262.  These findings suggest that HIV disease may be associated with mild, perhaps 
transient, glucose disorders but that traditional DM risk factors play a stronger role in the 
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progression to DM than HIV itself or the inflammatory processes to which it gives rise103.  
Alternatively, the association between HIV infection and IR, but not with DM, may simply 
indicate that IR precedes DM and that we had greater statistical power to detect this difference.  
Finally, because HAART use itself has been identified as a risk for IR among HIV-infected 
individuals100, it is plausible that the association between HIV and IR is confounded by HAART 
use and IR is not merely a direct result of HIV-infection. 
HAART use was not a significant risk factor for DM in our study but was found to be 
associated with incident IR.  Several explanations are possible for this finding.  HAART use, 
specifically protease inhibitors116, 131, 133, 134, 146, 267 as well as cumulative exposure to nucleoside 
reverse transcriptase inhibitors141, has been associated with elevated IR markers among HIV-
infected individuals.  It is also possible that our median follow-up time of 5 years was not long 
enough for IR to progress to DM, thus diminishing our ability to observe an association between 
DM and HAART use.  Likewise, simultaneous stratification by HIV and by HAART use reduced 
the sample size and limited the power to detect differences.  Finally, individual HAART 
regimens are heterogeneous with respect to effects on glucose metabolism100; therefore, using 
HAART as a drug exposure class may have reduced the effect of any individual medication or 
specific medication combinations. 
This study underscores the impact of diabetes definition on the incidence rates of DM, 
regardless of HIV infection.  The DM incidence rate in our study is lower than that initially 
published for the MACS 106 when using the more stringent diabetes definition; however when 
using the less stringent definition employed in our previous work106, the incidence rates were 
similar.  We previously reported a rate of 1.4 per 100 PY among HIV-uninfected men compared 
with our current findings of 0.9-2.9 per 100 PY depending on the definition used.  Similarly, for 
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HIV-infected men, the incidence rate of DM using the less stringent definition was comparable 
to our prior work (1.7 versus 2.5 per 100 PY in HAART naïve men106 and 4.7 versus 4.0 per 100 
PY in HAART users106). The additional requirement of a confirmatory fasting glucose 
substantially reduced these incidence rates (1.1 and 1.0 per 100 PY, respectively).   Other studies 
using confirmatory glucose concentrations also report low DM incidence rates.  Ledergerber et 
al.18  in their analysis of 6513 HIV-infected participants from the Swiss HIV Cohort Study, found 
a rate of 0.442 cases per 100 PY, while De Wit et al11 report a similar low incidence (0.572 per 
100 PY, 95% CI 5.31-6.13) in a cohort of 32,437 HIV-infected men and women in Europe, the 
US, Argentina, and Australia.   
The current study had two main limitations.  The number of persons developing DM was 
smaller than expected because of the stringent case definition that we used.  Thus, our power to 
detect differences may have been reduced, especially in analytic models stratified by HIV status.  
The secondary analyses using the less stringent definition increased the number of DM events; 
therefore our power to detect differences with this more sensitive and less specific definition was 
increased.  We also did not have the power to limit our analysis to men with normoglycemia at 
baseline; however mean physical function scores did not significantly differ between men with 
normoglycemia and men with pre-diabetes at baseline.   
Secondly, because the MACS never collected physical activity data, we were limited to 
the use of physical function.  Future studies with objective measures of physical activity are 
required to confirm our results. As previously discussed, numerous studies conducted among 
HIV-uninfected populations have established that physical activity levels are correlated with 
physical function performance.  Brach et al observed a correlation between pedometer readings  
and the Functional Status Questionnaire (r=0.34); the Physical Performance Test (r=0.41); and 
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gait speed (r=0.52) 15.  Cross-sectional and prospective studies suggest that low physical activity 
is an independent predictor of both measured and self-reported low physical function15-20.  While 
similar studies have not yet been conducted in HIV-infected cohorts, Roubenoff and Wilson 
reported an increase in physical function in HIV-infected patients with wasting who completed a 
resistance training program21.  Given these results, it is plausible to suggest that the men in our 
study with low physical function also had lower physical activity levels compared to men with 
higher physical function.   
 To our knowledge, this is the first prospective study to assess the contribution of physical 
function to incident DM and IR in a cohort that included both HIV-uninfected and HIV-infected 
men.   This study supports our previous findings that self-reported low physical function is an 
important risk factor DM in the MACS cohort.  These results underscore the clinical relevance of 
the association between physical function, BMI and DM.  Improved physical function in this 
population would likely result from an increase in physical activity and a decrease in BMI, two 
important factors known to reduce the incidence of DM.   Although future research using 
objective physical activity measures is necessary to further elucidate the contribution of low 
physical activity to DM and IR development in HIV-infected persons, ongoing studies 
addressing the issues of glucose metabolism in HIV-infected populations should include 





Table 9.  Characteristics of 1790 men at the index visit 








Age, mean (range) 43.1 (18.2-82.6) 44.9 (18.2-82.6) 40.6 (19.6-68.9) <0.001* 
White subjects, No (%) 1042 (58.2) 710 (69.4) 332 (43.3) <0.001* 
Body mass index, mean ++ 25.9 26.3 25.4 <0.001* 
Glucose level, mg/dL (mean) 89.5 89.3 89.9 0.3 
Insulin, µU/ml (mean) 13.5 12.7 14.4 <0.001* 
HOMA, µU/ml x mmol/L 
(mean) 
3.1 2.9 3.3 <0.001* 
CD4 count, cells/mm3 764.1 930.8 540.7 <0.001* 
Physical function, mean 86.0 88.2 83.0 <0.001* 
Family history of DM, No (%) 555 (31.1) 300 (29.5) 255 (33.3) 0.2 
History of smoking, No (%) 1163 (66.0) 628 (62.0) 535 (71.4) <0.001* 
Abbreviations: HIV: human immunodeficiency virus; DM: diabetes mellitus; HOMA: homeostasis model 
assessment 
* P < 0.05 comparing the HIV-uninfected men with the HIV-infected men using the Chi-square test or the 
Student’s t-test, as appropriate 





Table 10.  Baseline characteristics of men with high and low physical function stratified by HIV serostatus 
Abbreviations: HIV: human immunodeficiency virus; HOMA: homeostasis model assessment; 
AIDS: acquired immunodeficiency syndrome; HAART: highly active antiretroviral therapy 
High physical function > 80; Low physical function < 80 
* P < 0.05 using the Chi-square test or the Student’s t-test, as appropriate 
++Calculated as weight in kilograms divided by the square of the height in meters 


















Age, mean  44.0 47.7 <0.001* 40.4 41.0 0.3 
White subjects, No (%) 570 (73.5) 140 (56.5) <0.001* 253 (52.6) 79 (27.6) <0.001* 
Body mass index, mean ++ 26.2 26.6 0.2 25.3 25.4 0.9 
Glucose level, mg/dL (mean) 89.1 89.9 0.4 90.5 88.7 0.07 
Insulin, µU/ml (mean) 12.1 14.6 0.002* 14.3 14.7 0.7 
HOMA, µU/ml x mmol/L (mean) 2.7 3.3 0.003* 3.3 3.3 0.9 
CD4 count, cells/mm3 913.2 985.6 0.002* 565.3 499.4 0.003* 
Family history of DM, No (%) 232 (30.1) 68 (27.6) 0.4 158 (32.9) 97 (33.9) 0.9 
History of smoking, No (%) 446 (57.6) 182 (76.5) <0.001* 338 (70.2) 197 (73.5) 0.3 
AIDS, No (%) 














Table 11.  Cox regression for incident diabetes mellitus 









Model 1 (physical function) 1.34 1.13-1.59 1.34 1.22-1.50 
Model 2 (physical function, BMI) 1.24 1.04-1.49 1.30 1.17-1.44 
Model 3 (physical function, BMI, DM family history) 1.25 1.04-1.49 1.30 1.17-1.44 
Model 4 (physical function, BMI, DM family history, age) 1.24 1.04-1.49 1.30 1.17-1.44 
Model 5 (physical function, BMI, DM family history, age, race) 1.14 0.94-1.38 1.21 1.08-1.35 
HIV-uninfected men   
Model 1 (physical function) 1.50 1.22-1.83 1.43 1.25-1.63 
Model 2 (physical function, BMI) 1.36 1.08-1.73 1.33 1.15-1.56 
Model 3 (physical function, BMI, DM family history) 1.36 1.06-1.73 1.33 1.15-1.56 
Model 4 (physical function, BMI, DM family history, race) 1.31 1.02-1.66 1.29 1.11-1.50 
Model 5 (physical function, BMI, DM family history, race, age) 1.24 0.96-1.60 1.22 1.04-1.44 
Model 6 (physical function, BMI, DM family history, race, age, CD4) 1.23 0.94-1.63 1.20 1.02-1.41 
HIV-infected men   
Model 1 (physical function) 1.12 0.85-1.50 1.23 1.06-1.44 
Model 2 (physical function, BMI) 1.08 0.80-1.47 1.22 1.06-1.41 
Model 3 (physical function, BMI, age) 1.10 0.82-1.50 1.23 1.06-1.44 
Model 4 (physical function, BMI, age, race) 1.02 0.76-1.38 1.16 1.00-1.38 
Abbreviations: HR: hazard ratio; BMI: body mass index; DM: diabetes mellitus 
a DM defined using a confirmatory fasting glucose > 126 mg/dl 
b DM defined using a single fasting glucose > 126 mg/dl 
Note: physical function HR per 20 point decrease 
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Table 12.  Cox regression for incident insulin resistance 
All men 
 Physical Function HR 95% Confidence Interval 
Model 1 (physical function) 1.15 1.04-1.27 
Model 2 (physical function, BMI) 1.09 0.96-1.22 
Model 3 (physical function, BMI, age) 1.07 1.00-1.20 
Model 4 (physical function, BMI, age, DM family history) 1.15 1.02-1.30 
Model 5 (physical function, BMI, age, DM family history, HIV) 1.14 1.00-1.30 
HIV-uninfected men 
Model 1 (physical function) 1.20 1.04-1.38 
Model 2 (physical function, BMI) 1.00 0.84-1.17 
Model 3 (physical function, BMI, CD4) 1.01 0.84-1.17 
Model 4 (physical function, BMI, CD4, DM family history) 1.01 0.84-1.22 
HIV-infected men 
Model 1 (physical function) 1.08 0.94-1.25 
Model 2 (physical function, age) 1.07 0.94-1.25 
Model 3 (physical function, age, BMI) 1.11 0.96-1.30 
Model 4 (physical function, age, BMI, HAART) 1.10 0.94-1.27 
Abbreviations: HR: hazard ratio; BMI: body mass index; HAART: highly active antiretroviral therapy 
Insulin resistance was defined as the highest homeostasis model assessment (HOMA) quintile in our data (>4.3 µU/ml x mmol/L) 




Figure 2.  Kaplan-Meier survival curve for incident DM among HIV-uninfected and HIV-infected men with high and low physical function at 
baseline using the more stringent definition of diabetes and less stringent definition of diabetes, respectively
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Aims: To assess associations between self-reported physical function and performance-based 
measures of physical function, diabetes mellitus (DM), and insulin resistance (IR). 
Methods: We analyzed cross-sectional data from 2079 HIV-infected and uninfected men in the 
Multicenter AIDS Cohort Study (MACS).  DM was defined as a fasting glucose of >126 mg/dl 
or self-reported diagnosis of diabetes and use of diabetes medication.  IR was calculated using 
the homeostasis model assessment.  The Physical Functioning Ten Scale measured self-reported 
physical function.   Handgrip strength and gait speed were used as performance-based measures.  
Spearman rank order correlation coefficients and logistic regression models assessed 
relationships between measures of physical function, DM and IR. 
Results: Self-reported physical function and performance-based measures were weakly 
correlated.  (HIV-uninfected: ρ=0.12-0.23, p<0.01; HIV-infected ρ=0.16-0.24, p<0.01).  Among 
HIV-uninfected men, self-reported physical function was more strongly associated with DM than 
grip strength or gait speed.  This trend remained after adjustment for covariates (physical 
function AOR 1.22, p=0.14 vs grip strength AOR 1.13, p=0.14 in men with DM).  Among HIV-
infected men, handgrip strength was the only physical function measure associated with DM 
(AOR 1.16, p=0.06).  Self-reported physical function was significantly associated with IR in 
HIV-uninfected men in multivariate analysis (AOR=1.43, p<0.001).  None of the physical 
function measures were significantly associated in HIV-infected men with IR. 
Conclusions:  Our results suggest that both self-report and performance-based measures of 
physical function should be used in a complementary manner in order to gain a comprehensive 
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understanding of physical function among individuals with HIV-infection.  The associations 
between self-reported physical function and grip strength with DM and IR in the MACS support 




Older adults now comprise a greater proportion of HIV-infected individuals due to the success of 
highly active antiretroviral therapy (HAART) as well as an increase in new infections among 
adults older than age 5099, 219. It is necessary for researchers and clinicians to address not only 
HIV infection but also co morbidities associated with the normal aging process, which may be 
accelerated in HIV-infected individuals.260  In fact, Oursler et al demonstrated that co morbid 
conditions were associated with impaired physical function independent of HIV status220.   
Maintaining physical function has been shown to be a key aspect of healthy aging in the general 
population221 and will become more of a focus in HIV-infected individuals as HAART use 
continues to slow disease progression220.  Lower self-reported physical function has been 
observed among individuals with HIV infection and AIDS compared to HIV-uninfected 
counterparts231, 262.   
Self-report questionnaires provide insight into an individual’s perception of ability but 
are often influenced by psychosocial factors including mood, cognition, expectations, reporting 
bias, attitudes, and emotional distress223, 230.  Therefore, measures of self-report among HIV-
infected individuals may not accurately reflect an individual’s actual functional ability.  
Simmonds et al suggest that measured physical performance was worse among HIV-infected 
men and women compared with healthy individuals; however this study did not compare these 
results to self-reported function230.   
Studies of patients with fibromyalgia, low back pain, and rheumatoid arthritis have 
demonstrated that the relationship between self-report and performance-based physical function 
102 
measures ranges from fair to good223, 228, 268.  Similar studies have not yet been conducted in 
HIV-infected participants.  Clarifying this relationship may provide insight into the overlap 
between self-report and performance-based measures in this population.  This is important to 
gain a comprehensive understanding of physical function among individuals with HIV infection.   
Individuals living with HIV infection are faced with co-morbidities that are common in 
the general population.  Diabetes mellitus (DM) and insulin resistance (IR) are two such 
conditions.  To date, the etiology of DM and IR in HIV-infection remains unclear.  Traditional 
risk factors such as advancing age10, 269 and higher BMI10, 269 have consistently been reported and 
HIV specific risk factors such as HAART use100, 110 are thought to play a role.  We have shown 
that self-report physical function is associated with DM and IR in the Pittsburgh component of 
the Multicenter AIDS Cohort Study (MACS)262; however the role of performance-based 
functional measures has not been assessed in HIV-infected populations.   
Handgrip strength was negatively associated with fasting insulin levels (p=0.013) in a 
cohort of community-dwelling HIV-uninfected men and women245, 270.  In addition, the 
prospective analysis found that handgrip strength was predictive of fasting insulin 23 years after 
baseline adjusting for age, BMI, and ratio of abdominal girth to hip breadth245.  The authors 
suggest that skeletal muscle weakness may predict the development of IR and subsequent DM.  
Given our observation that self-reported low physical function in HIV-infected men is associated 
with DM and IR, it is plausible to suggest that markers of function such as grip strength and gait 
speed may also be associated with IR and DM in HIV-infected individuals.  It is imperative to 
identify early predictors of glucose disorders to help prevent the chronic complications 
associated with their progression22, 25.  This is especially important for individuals with HIV-
infection who are already at risk for physical disability due to HIV associated symptoms220. 
103 
 This cross-sectional study uses data from the Multicenter AIDS Cohort Study 
(MACS) to assess the correlation between self-reported physical function and performance-based 
measures of physical function including gait speed and grip strength.  It also compares 
multivariate models to determine if performance-based measures of physical function are more 
strongly associated with diabetes mellitus and insulin resistance than are self-reported measures. 
 
4.3 METHODS 
4.3.1 Study Participants 
All study participants were from the Multicenter AIDS Cohort Study (MACS).  The MACS is an 
ongoing multicenter (Baltimore, MD; Chicago, IL; Los Angeles, CA; and Pittsburgh, PA) natural 
history prospective cohort study of HIV infection.  It was designed to gather information on the 
epidemiology, virology, immunology, and pathology of HIV.  Homosexual and bisexual men 
aged > 18 years without AIDS were recruited from the local communities in three recruitment 
cycles (April 1984-March 1985; April 1987-September 1991; October 2001-August 2003).  The 
second and third cycles focused on increasing the proportion of minority participants. Briefly, 
the MACS follows a 6-month visit schedule and involves detailed data collection regarding 
medical history, physical examination, and collection of biological specimens. Institutional 
review boards at each site approved the MACS protocol, and each participant provided informed 
consent.  Further detail can be found in Kaslow et al and Silvestre et al 263, 271.   
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The current study includes subjects in the MACS cohort during visit 48 (October 1, 2007-
March 31, 2008).  This date was chosen for three reasons: 1) to ensure the completion of the 
third recruitment wave (October 2001-August 2003); 2) to ensure the inclusion of grip strength 
and gait speed data which was added during visit 44; 3) to ensure the inclusion of the self-report 
physical function questionnaire which is administered every other visit (even visits).  Two 
thousand seventy nine men from the MACS were eligible for inclusion in this analysis. 
4.3.2 Exposure: Measures of Physical Function 
4.3.2.1 Self-Report 
The Physical Functioning Ten (PF 10) Scale from the Medical Outcomes Study (MOS) Short 
Form-36 (SF-36) Health Survey measured self-reported physical function.  The SF-36 is one of 
the most widely used Health Related Quality of Life Instruments and consistently demonstrates 
high levels of both reliability and validity in HIV-uninfected249-251 and HIV-infected 
populations272-276.  Specifically, in the MACS cohort264, internal consistency estimates ranged 
from 0.85 to 0.86 depending on the SF-36 scale while the factor structure was found to be similar 
to previously documented factor structures in both the general population and in other diseases. 
This study includes data from PF 10 questionnaires administered at visit 48.  During the 
administration of the PF 10, participants were asked the following question regarding physical 
activities that might be done in a typical day: “Does you health now limit you in these activities?  
If so, how much?”  Participants chose between “Yes, limited a lot”, “Yes, limited a little”, or 
“No, not limited at all” for vigorous activities (running, lifting heavy objects); moderate 
activities (vacuuming, golf); lifting or carrying groceries; climbing several flights of stairs; 
climbing one flight of stairs; bending, kneeling, or stooping; walking more than a mile; walking 
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several blocks; walking one block; bathing or dressing (Table 1).  Each item was scored on a 0 to 
100 range as follows: 100= not limited at all; 50= limited a little; and 0= limited a lot, based on 
the RAND scoring method252.  A mean score for the 10 activities was then calculated to 
determine an overall score for the PF 10 ranging from 0 to 100 with a score of 100 indicating 
that a participant’s health did not limit his ability to complete the physical activity tasks.  Thus, a 
lower score indicates lower physical function.   
4.3.2.2 Performance-based 
Handgrip strength and gait speed were used as performance-based measures of physical function 
and strength.  Grip strength was measured using a calibrated, Jamar dynamometer.  Each 
participant was asked to place his dominant arm on a table at a 90 degree angle to his body and 
to squeeze the dynamometer as hard as possible.  Three measurements of grip strength were 
taken with the dynamometer reset to zero prior to each reading.  A mean of the three 
measurements was calculated for each participant to obtain his overall grip strength (in 
kilograms).  Normal grip strength for adult males aged 40-75+ ranges from 29.8-53.0 kg 
depending upon age277.  
Gait speed was measured using a 4-meter walking course.  Participants were instructed to 
place their feet with their toes behind, but touching, the start line and to walk at their usual pace 
from a standing start.  Participants completed the walk twice.  Gait speed was determined by 
dividing the distance walked in meters by the time in seconds.  A mean of the 2 gait speeds was 
calculated for use in the analysis.  Normal gait speed for adults ranges from 1.2-1.3 m/s278, 279.  
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4.3.3 Outcome: Diabetes Mellitus and Insulin Resistance 
Diabetes was defined as either a fasting glucose concentration of >126 mg/dl or self-reported 
diagnosis of diabetes and use of diabetes medications; consistent with the Center for the Analysis 
and Management of the MACS Data (CAMACS) algorithm for prevalent DM.   Self-reported 
DM was determined using the following questions: “Since your last visit have you been told by a 
practitioner that you have diabetes?”; “Have you ever been told that you have high blood sugar 
or diabetes?”; “Have you seen a doctor or other medical practitioner for any condition since your 
last visit? If yes, was there a diagnosis for your condition?”  Men who listed a diagnosis of 
diabetes were included.  Antidiabetic medication use was obtained from a report of medications 
used since the previous visit.  A fasting glucose concentration of > 126 mg/dl is consistent with 
American Diabetes Association Guidelines22.  
Insulin concentrations were also obtained from the fasting serum samples.  Insulin 
resistance was estimated using the homeostasis model assessment (HOMA): (fasting insulin 
[(µU/ml] x fasting glucose [mmol/L)]/22.5248.  Glucose levels were converted to mmol/L by 
dividing mg/dl by 18.  Insulin resistance was defined by the highest HOMA quintile in our data 
(> 4.29 µU/ml x mmol/L). 
4.3.4 Covariates 
Covariates of interest, taken from visit 48,  included age, race (white/non-white), HIV status, 
AIDS status, HAART status (yes/no), lipoatrophy257, CD4 count, body mass index (BMI), and 
family history of DM.  Lipoatrophy was defined as examiner observed moderate or severe 
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atrophy in at least one of the following four sites: face, arm, leg, buttocks.  These covariates were 
chosen because of their association with physical function or diabetes development253, 254.    
4.3.5 Data Analysis 
SAS Version 9.2 was used for all statistical analyses.  Chi-square tests and the Student’s t-test 
were used to test for differences in proportions and distributions of physical function measures, 
covariates and disease status between HIV serostatus groups.  The relationship between self-
reported and performance-based measures of physical function was examined using Spearman 
rank order correlation coefficients.   
Univariate logistic regression analysis was performed to assess unadjusted associations 
between covariates and the outcomes of interest, DM and IR.  Multivariate logistic regression 
models using a stepwise methodology were constructed to assess the independent association 
between self-report physical function, gait speed and handgrip strength with diabetes and insulin 
resistance after adjusting for important covariates.  Covariates with a p-value of < 0.3 in 
univariate analysis were chosen for the multivariate models.  Among the chosen covariates from 
univariate analysis, those with a p-value < 0.25 initially entered the model while covariates with 
p-values of < 0.15 remained in the final model. 
4.4 RESULTS 
The characteristics of the 2079 men at visit 48, stratified by HIV serostatus, are presented in 
Table 13.  Of these men, 1082 were HIV-uninfected and 997 were HIV-infected.  The HIV-
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infected men were younger, had a lower mean BMI, a higher percentage of non-white 
participants, and lower CD4 counts compared with their HIV-uninfected counterparts.  Family 
history of DM was similar between the 2 groups.  Glucose levels did not differ significantly 
between HIV-serostatus groups; however both fasting insulin levels and mean HOMA were 
higher in HIV-infected men.  The proportion of men with DM and IR did not differ by HIV 
serostatus.  Although mean self-reported physical function scores were lower in the HIV-infected 
men compared with the HIV-uninfected men (84.6 and 87.5 respectively, p=0.004), grip strength 
was higher men with HIV infection (39.4 kg versus 38.4 kg, p=0.03).  Mean gait speed was 
identical in both groups (1.1 m/sec).  Of the HIV-infected men, 14.7% had AIDS, 16.1% had 
lipoatrophy, and 89.9% were using HAART at visit 48. 
The correlations between self-report physical function and the performance-based 
measures, although significant, were weak regardless of HIV serostatus (Table 14).  The weakest 
of these associations was the correlation between gait speed and handgrip strength (ρ=0.07, 
p<0.01, all men).  The correlations between PF-10 score and handgrip strength were higher 
(ρ=0.14, p<0.01, all men).  This association was somewhat stronger in HIV-infected men than in 
HIV-uninfected men (ρ=0.16 and ρ=0.12 respectively).  The strongest of the associations was 
observed between PF-10 score and gait speed (ρ=0.23, p<0.01, all men).   The correlations were 
similar in HIV-infected versus HIV-uninfected men (ρ=0.24 and ρ=0.23 respectively). 
Table 15 shows mean PF-10 scores for men with the slowest gait speed and weakest 
handgrip (Quartile 0-25%), men with intermediate gait speed and intermediate grip handgrip 
(Quartiles 25-75%), and men with the fastest gait speed and strongest handgrip (Quartile (75-
100%) stratified by HIV serostatus.  Men who did not fall into one of these categories were not 
included.  Self-report physical function did not differ by HIV-status in any of the quartiles.  The 
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scores were higher among the men with the fastest gait speed and strongest grip strength 
compared to the men with the slowest gait and weakest grip.  This trend was most pronounced in 
the HIV-infected men with a difference of 15 between the highest and lowest quartiles (93.20 
versus 78.46).  HIV-infected men had lower self-reported physical function scores in each of the 
quartiles, although these differences were not significant. 
In univariate analysis (Table 16), lower physical function score (odds ratio (OR): 1.40 per 
20 unit decrease, 95% CI 1.22-1.50), weaker grip strength (OR: 1.19 per 5 unit decrease, 95% CI 
1.05-1.29), older age (OR: 1.21 per 5 year increase, 95% CI 1.10-1.34), higher BMI (OR: 1.10 
per unit increase, 95% CI 1.06-1.13), and non-white race (OR: 1.68, 95% CI 1.21-2.33) were 
associated with DM among all men.  Family history of DM, HIV serostatus, CD4 count, gait 
speed (per unit decrease) and the first-order interaction between HIV serostatus and physical 
function score were not associated with DM in univariate analysis.  However, in multivariate 
analysis, HIV serostatus (adjusted odds ratio (AOR): 2.05, 95% CI 1.27-3.33) became 
significantly associated with DM in addition to weaker grip strength (AOR: 1.13 per 5 unit 
decrease, 95% CI 1.05-1.29), older age (AOR: 1.30 per 5 year increase, 95% CI 1.16-1.47), 
higher BMI (AOR: 1.10 per unit increase, 95% CI 1.06-1.15), and non-white race (AOR: 1.98, 
95% CI 1.24-3.18).  Self-reported physical function (AOR: 1.19 per 20 unit decrease, 1.00-1.50) 
and CD4 count (AOR 1.04 per 100 unit increase, 95% CI 1.00-2.70) were of borderline 
significance.   
Similar covariates were also significantly associated with DM in univariate and 
multivariate analysis among HIV-uninfected men.  Lower physical function score (OR: 1.55 per 
20 unit decrease, 95% CI 1.22-1.84), weaker grip strength (OR: 1.20 per 5 unit decrease, 95% CI 
1.05-1.36), older age (OR: 1.19 per 5 year increase, 95% CI 1.05-1.34), higher BMI (OR: 1.14 
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per unit increase, 95% CI 1.09-1.20), non-white race (OR: 2.05, 95% CI 1.27-3.32), and CD4 
count (OR: 1.11 per 100 unit increase, 95% CI 1.00-2.70) were associated with DM in univariate 
analysis.  In multivariate analysis, there were borderline significant trends towards associations 
between DM and lower physical function score (AOR: 1.22 per 20 unit decrease, 95% CI 1.00-
1.50) and weaker grip strength (AOR: 1.13 per 5 unit decrease, 95% CI 0.95-1.36).  Older age, 
higher BMI, non-white race and CD4 count all remained significantly associated with DM in 
multivariate analysis. 
Among HIV-infected men, only lower physical function score (OR: 1.25 per 20 unit 
decrease, 95% CI 1.00-1.50), weaker grip strength (OR: 1.20 per 5 unit decrease, 95% CI 1.05-
1.36), and older age (OR: 1.32 per 5 year increase, 1.16-1.54) were associated with DM in 
univariate analysis.  Lipoatrophy was not associated with DM in univariate analysis.  In 
multivariate analysis, older age (AOR: 1.37 per 5 year increase, 95% CI 1.16-1.69) was the only 
covariate to remain significantly associated with DM.  Self-reported physical function did not 
remain in the model while non-white race (AOR: 1.87, 95% CI 1.00-3.48) and weaker grip 
strength (AOR: 1.17 per 5 unit decrease, p=0.06) and BMI (AOR: 1.06 per unit increase, 95% CI 
0.99-1.13) were of borderline significance.   
Table 16 also shows univariate and multivariate associations with IR.  Among all men, 
physical function score (AOR: 1.24 per 20 unit decrease, 95% CI 1.22-1.50), BMI (AOR: 1.23 
per unit increase, 95% CI 1.19-1.27), older age (AOR: 1.09 per 5 year increase, 95% CI 1.00-
1.16) and HIV serostatus (AOR: 1.88, 95% CI 1.37-2.58) were significantly associated with IR 
in multivariate analysis. 
In HIV-uninfected men, physical function score (AOR: 1.45 per 20 unit decrease, 95% CI 
1.22-1.84), BMI (AOR: 1.27 per unit increase, 95% CI 1.20-1.33), and CD4 count (AOR: 1.00 
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per 100 unit increase, 95% CI 1.00-2.70) were all associated with IR in the multivariate model.  
Finally, among HIV-infected men, BMI (AOR: 1.17 per unit increase, 95% CI 1.11-1.22) was 
the only variable significantly associated with IR in multivariate analysis; however there were 
also non-significant trends towards associations with IR and older age (AOR: 1.12 per 5 year 
increase, 95% CI 0.95-1.28) and non-white race (AOR 1.08, 95% CI 0.97-1.21). 
4.5 DISCUSSION 
This study is one of the first to assess the association between self-reported and performance-
based measures of physical function in HIV-infected men and to assess these measures as risk 
factors for DM and IR.  Significant but weak associations were found between gait speed and 
grip strength with the SF-36 PF-10 scale. Correlations were slightly higher among HIV-infected 
men. The weak correlations observed in our study suggest that self-reporting of physical abilities 
may not accurately reflect an individual’s actual functional ability, regardless of HIV serostatus, 
but that other psychosocial factors such as mood, cognition, expectations, attitudes, and 
emotional distress may also play an important role in an individual’s perception of function223. 
The strongest association was observed between gait speed and the PF-10, regardless of 
HIV serostatus.  This was not surprising given the nature of the PF-10 questionnaire.  The 
majority of items (6 of the 10) on the PF-10 scale focus on the lower extremities, specifically on 
walking distances and stair climbing; therefore a stronger correlation with gait speed was 
expected.   
Numerous studies have assessed the association between self-report and performance-
based measures of physical function in HIV-uninfected populations.  The results across studies 
112 
are comparable to our findings and suggest that performance-based measures are low to 
moderately correlated with measures of self-report222-227.  Correlation coefficients in studies 
among older adults, patients with low back pain, and patients with fibromyalgia were similar and 
ranged from 0.1 to 0.6 depending on the task and self-report questionnaire used222, 223, 226, 228, 229. 
Lee et al, in their cross-sectional analysis of men and women with low back pain, reported 
correlations ranging from -0.09 to -0.41 between the Roland-Morris Disability Questionnaire and 
a physical performance test battery223.  Mannerkorpi et al found slightly higher correlations in 
their study of women with fibromyalgia228.  Their six-minute walk test and measure of handgrip 
strength showed fair to good correlations with the SF-36 PF-10 scale (ρ=0.48 and ρ=0.52, 
respectively).  It is important to note that this study was conducted entirely in women, making 
comparisons with our study limited.   
The lack of a stronger correlation is likely due to the fact that performance-based and 
self-report measures assess different aspects of the physical function construct226.  While 
performance-based measures examine an individual’s actual ability to complete a task through 
performance observation, measures of self-report rely on an individual’s perception of his or her 
ability to complete the task226.  Given these results, it is reasonable to suggest that the most 
accurate method of measuring physical function in HIV-infected populations may be a 
complementary approach using both self-report and performance-based measures as subjective 
measures may provide useful information beyond that obtained solely on observation226.  The 
relatively weak correlations reported in our study coupled with no better than moderate-to-good 
correlations in the above studies support the notion that psychosocial factors may be involved in 
self-reported physical function among HIV-infected individuals223.  
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Interestingly, the results of our study indicate that the performance-based measures of 
physical function were similar in HIV-infected and HIV-uninfected men despite significantly 
lower self-reported scores in the HIV-infected men.  Our study suggests that, in the MACS 
cohort, HIV serostatus did not have an effect on actual physical performance but did impact a 
participant’s perception of his functional abilities.  A few explanations for this finding are 
possible.  Firstly, individuals living with a chronic disease, specifically one that is present for a 
prolonged period of time and that is influenced by waxing and waning symptoms may make it 
difficult for an individual to judge functional declines230.  Secondly, the psychosocial impact of 
living with a chronic disease on mood, cognition, expectations, reporting bias, attitudes, and 
emotional distress may influence an individual’s perception of his functional ability227.  Finally, 
the potential side effects of HAART such as nausea, diarrhea, and vomiting280 may influence 
self-reported physical function without impacting actual physical performance.  Regardless, the 
similarity in physical function between the HIV-uninfected and infected men is encouraging and 
indicates that men infected with HIV are capable of functioning at levels that comparable with 
their HIV-uninfected peers. 
Previous studies report conflicting results when comparing physical function in HIV-
infected and uninfected populations.  Simmonds et al utilize both performance-based and self-
reported measures in their study of the differential influence of pain and fatigue on physical 
performance in HIV-infected men and women230.  Their study suggests that physical 
performance among HIV-infected individuals was much lower than “age-equivalent healthy 
patients.”  However, a large percentage of their population (48%) were classified as having 
AIDS and may represent a sicker, thus more functionally impaired cohort of HIV-infected 
individuals compared with the men in the MACS cohort.  In contrast, two studies by Oursler et al 
114 
found similar levels of physical functioning among HIV-infected and HIV-uninfected 
participants.  Their found no significant difference in the unadjusted mean physical disability 
score when stratified by HIV serostatus (p=0.4)220.  In addition, the proportion of participants 
who reported difficulties with basic activities of daily living (ADLs), mobility, and vigorous 
activities was similar in HIV-infected and uninfected participants (p>0.05 for all activities).  A 
second study by Oursler utilized functional performance testing234.  They found that the mean 6-
min walk distance was reduced only 8% in HIV-infected men compared to expected values for 
healthy adults (adjusted for age, gender, and BMI).  After stratification by age, only the middle-
aged (50-59 years) HIV-infected men had significantly reduced grip strength as compared to 
published values for healthy men of similar age (p=0.02).  Grip strength was reduced by 10% 
(41.3 kg vs. 46.2 kg) in HIV-infected adults using a weighted average.  Finally, a study by Bauer 
et al compared measures of balance and gait between 78 HIV-uninfected volunteers to 28 HIV-
infected participants receiving no antiretroviral therapy, 25 receiving only nucleoside analogue 
therapy, and 37 participants receiving HAART235.  They found no significant differences in 
measures of proximal strength, gait speed and cadence between any of the groups.   
The results of our logistic regression analysis indicate that, in the MACS cohort, self-
report physical function appears to be more strongly associated with DM and IR than either grip 
strength or gait speed. These results are consistent with our previously published findings that 
self-report physical function is associated with DM and IR in HIV-infected and uninfected 
men262.   The unadjusted OR was higher for the self-report physical function measure compared 
with grip strength regardless of HIV serostatus.  This trend remained after adjustment for 
covariates; however grip strength among all men was the only physical function covariate 
significantly associated with DM in the multivariate model.  Conversely, self-report physical 
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function score the only measure of physical function significantly associated with IR in all men 
and HIV-uninfected men.  None of the physical function measures where associated with IR in 
the HIV-infected men.  Gait speed was not associated with either IR or DM, likely due to the 
small standard deviation range in both HIV-infected (1.1 m/sec + 0.19) and HIV-uninfected (1.1 
m/sec + 0.18) men.  A recent study by Brach et al found an association between gait speed and 
diabetes; however comparisons with our study are difficult given their much older population 
(mean age 79 years).  
One possible explanation for our findings that self-reported physical function was more 
strongly associated with DM is that individuals living with a chronic disease such as DM may 
perceive their functional abilities to be lower than actual performance. The weak correlations 
between self-report measures and grip strength in our study support this notion.  Interestingly, 
self-reported physical function was not associated with having the combination of both DM and 
HIV in multivariate analysis; however it is possible that, due to limited power, the strength of 
traditional risk factors such as age, BMI, and race outweighed any association with self-report 
physical function.  Finally, it is possible that the questions on the PF-10 that addressed the 
difficult physical function tasks (i.e. ability to walk 1 mile) were able to capture participants with 
more severe functional limitations as compared with the simpler gait speed and grip strength 
measures. 
Despite its slightly weaker association with DM, the inclusion of grip strength in all DM 
models deserves attention.  The borderline significant association among HIV-infected men is of 
particular interest.  This suggests that lower skeletal muscle strength among these men may serve 
as a marker for DM.  Insulin-mediated glucose uptake takes place mostly in skeletal muscle and 
is directly related to the amount of muscle mass while inversely associated with fat mass.  
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Skeletal muscle is an important site for the disposal of glucose during carbohydrate loading 
which appears to be assisted by insulin.  Therefore, it is biologically plausible that changes in the 
physiology of skeletal muscle may result in lower levels of muscle strength, peripheral 
sensitivity to insulin with decreased tolerance to carbohydrate loading and thus eventual  
DM3, 6, 245. 
Although prospective studies are necessary to verify associations between low grip 
strength and the development of diabetes, our result is encouraging because identifying early 
functional markers of glucose disorders may help prevent further functional declines and chronic 
complications associated with their progression22, 25.   This is essential for individuals with HIV-
infection who are already at risk for physical disability due to HIV associated symptoms220.  
However, it is important to note that the lack of association between grip strength and IR may 
indicate that the decreased strength observed in men with DM is a result of complications 
associated with diabetes itself or that the decrease in strength occurs somewhere in the 
continuum between IR and DM.  
Few studies have assessed measures of physical function as risk factors for glucose 
disorders despite recent literature showing that the loss of muscle mass and strength with age is 
associated with type 2 DM238, 242.  None of these studies were conducted in HIV-infected 
populations.  Lazarus et al examined the cross-sectional and prospective relationships between 
handgrip strength and fasting insulin levels in 655 men from the Normative Aging Study 
cohort245.  Although handgrip strength was not significantly correlated with unadjusted fasting 
insulin levels (r=-0.06), a negative cross-sectional association was observed after adjustment for 
confounders (p=0.013).  In their prospective analysis, higher baseline handgrip values predicted 
lower fasting insulin levels twenty years later (p=0.017).  The authors suggest that skeletal 
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muscle weakness serves as a marker for an increased risk of hyperinsulinemia and may 
ultimately predict the development of insulin resistance.  A cross-sectional study by Sayer et al 
assessed the relationship between grip strength and metabolic syndrome in 1684 men and women 
born in Hertfordshire United Kingdom.  The HOMA formula was used a marker of IR while  
DM and IGT were classified using a 2 hour glucose concentration.  They reported a significant 
association between lower handgrip strength and a higher 2 hour glucose (0.07 standard 
deviation increase, p=0.001) and with an increased HOMA. 
When interpreting our findings, the limitations of the study must be considered.  Given 
the cross-sectional design, the direction of the association between measures of physical function 
and DM and IR cannot be determined.  Therefore, it is possible that the lower physical function 
scores and handgrip values are a result of the diabetes, rather than a precursor to its onset.  
Current literature does imply that complications associated with DM and IR may lead to 
functional impairments and reduced muscular strength236, 237, 239, 240, 242.  However, Lazarus et al, 
report a prospective association between grip strength and elevated fasting insulin levels and 
suggest a biologically plausible link between lower muscular strength and the development of 
IR245.   In addition, the fasting glucose measurements used to define a diabetes case were taken 
from visit 48 only and were not confirmed at a subsequent visit.  Therefore, it is possible that 
misclassification of DM cases occurred, potentially over-inflating relationships between 
covariates and the DM outcome.  We were unable to complete a prospective analysis which 
would have allowed us to confirm glucose concentrations because gait speed and grip strength 
were not added until visit 44 (October 1, 2005-March 31, 2006).  The short period of follow-up 
substantially limited our power; therefore, a cross-sectional analysis was necessary.  Future 
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research using prospective studies is essential to further assess the role of performance-based 
measures of physical function as risk factors for DM and IR in HIV-infected populations. 
Our findings show that among HIV-infected men, self-report physical function and 
performance-based measures correlate weakly.  Therefore, each component may provide 
independent information with respect to the physical function construct indicating that both types 
of measures should be used in a complementary manner in order to gain a comprehensive 
understanding of physical function among individuals with HIV-infection.   
In addition, self-report physical function and upper limb weakness were found to be associated 
with DM in the MACS men indicating that early interventions aimed at increasing function and 
strength may help to attenuate DM risk.  Our results support the need for prospective studies 










Age, mean (range) 52.8 (22.7-82.8) 49.5 (22.7-79.5) <0.0001+ 
White subjects, No (%) 836 (77.3) 632 (63.4) <0.0001+ 
Body mass index, mean ++ 27.1 25.5 <0.0001+ 
Glucose level, mg/dL (mean) 101.4 101.0 0.8 
Prevalent diabetes, No (%) 88 (11.7) 87 (14.1) 0.18 
Insulin, µU/ml (mean) 13.4 15.4 0.006+ 
HOMA, µU/ml x mmol/L (mean) 3.5 4.0 0.05+ 
Insulin resistance*, No (%) 167 (22.2) 166 (26.2) 0.08 
CD4 count, cells/mm3 937.2 563.0 <0.0001+ 
Physical function, mean + SD 
Grip strength, kg mean + SD  
Gait speed, m/sec mean + SD 
87.5 + 21.2 
38.4 + 8.62 
1.1 + 0.18 
84.6 + 22.6 
39.4 + 8.99 




Family history of DM, No (%) 29 (3.2) 19 (2.2) 0.4 
History of smoking, No (%) 595 (57.5) 582 (62.3) 0.03+ 
AIDS, No (%) N/A 146 (14.7) N/A 
Lipoatrophy, No (%) N/A 132 (16.1) N/A 
HAART, No (%) N/A 896 (89.9) N/A 
Abbreviations: HIV: human immunodeficiency virus; HOMA: homeostasis model assessment;  
DM: diabetes mellitus; AIDS: acquired immunodeficiency syndrome; HAART: highly active 
antiretroviral therapy: SD; standard deviation 
*Insulin resistance defined as the highest HOMA quintile in our data (> 4.29 µU/ml x mmol/L). 
+ P < 0.05 comparing the HIV-uninfected men with the HIV-infected men using the Chi-square 
test or the Student’s t-test, as appropriate 
++Calculated as weight in kilograms divided by the square of the height in meters.
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Table 14.  Relationships between self-report and performance-based measures of physical function by Spearman rank order 
correlations stratified by HIV serostatus 



















PF-10 scale - 0.23* 0.14* - 0.23* 0.12* - 0.24* 0.16* 
Gait Speed  - 0.07*  - 0.04  - 0.09+ 




Table 15.  Mean self-reported physical function ten scores by gait speed and handgrip strength quartile, stratified by HIV 
serostatus 







 Mean physical function ten score 
Slowest gait speed and weakest handgrip (Quartile 0-25%), N=596 80.78 82.75 78.46 0.08 
Intermediate gait speed and intermediate handgrip (Quartiles 25-75%), N=377 88.80 89.78 87.77 0.29 
Fastest gait speed and strongest handgrip (Quartile 75-100%), N=91 93.68 94.27 93.20 0.71 
Abbreviations: HIV: human immunodeficiency virus 
++ P value comparing the HIV-uninfected men with the HIV-infected men  
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Table 16.  Logistic regression analysis of factors associated with diabetes and insulin resistance among HIV-uninfected and HIV-infected men at visit 48 
Risk Factor Unadjusted OR 
 
95% CI AOR 
 
95% CI Unadjusted OR 
 
95% CI AOR 
 
95% CI 
 Diabetes  Insulin resistance (HOMA-IR)  
All men 
Physical function-10 score+ 1.40 1.22-1.50 1.19 1.00-1.50 1.31 1.22-1.50 1.24 1.22-1.50 
Handgrip strength++ 1.19 1.05-1.29 1.13 1.05-1.29 1.00** 0.91-1.11   
Gait speed 1.01* 0.43-3.09   1.97** 0.91-4.26   
Age+++  1.21 1.10-1.34 1.30 1.16-1.47 1.04 0.95-1.10 1.09 1.00-1.16 
BMI 1.10 1.06-1.13 1.10 1.06-1.15 1.21 1.18-1.25 1.23 1.19-1.27 
HIV Status 1.24 0.90-1.71 2.05 1.27-3.33 1.25 0.98-1.60 1.88 1.37-2.58 
Race (reference: white) 1.68 1.21-2.33 1.98 1.24-3.18 1.42** 1.09-1.85   
Family DM 1.12* 0.81-1.56   1.12** 0.86-1.44   
CD4++++ 1.04 1.00-2.70 1.07 1.00-2.70 1.03** 1.00-2.70   
HIV-uninfected men 
Physical function-10 score+ 1.55 1.22-1.84 1.22 1.00-1.50 1.54 1.22-1.84 1.43 1.22-1.84 
Handgrip strength++ 1.20 1.05-1.36 1.13 0.95-1.36 1.03** 0.91-1.16   
Gait speed 0.54* 0.14-2.11   2.81** 0.94-8.40   
Age+++ 1.19 1.05-1.34 1.26 1.05-1.47 1.05** 0.95-1.16   
BMI 1.14 1.09-1.20 1.13 1.07-1.19 1.30 1.23-1.36 1.27 1.20-1.33 
Race (reference: white) 2.05 1.27-3.32 2.27 1.13-4.55 1.55** 1.04-2.31   
Family DM 0.57* 0.70-1.74   1.07** 0.75-1.52   
CD4++++ 1.11 1.00-2.70 1.09 1.00-2.70 1.10 1.00-2.70 1.00 1.00-2.70 
HIV-infected men  
Physical function-10 score+ 1.25* 1.00-1.50   1.10** 1.00-1.22   
Handgrip strength++ 1.20 1.05-1.36 1.17 1.00-1.50 1.00** 0.86-1.11   
Gait speed 2.60* 0.62-10.87   1.39** 0.47-4.10   
Age+++ 1.32 1.16-1.54 1.37 1.16-1.69 1.07 0.95-1.16 1.12 0.95-1.28 
BMI 1.04 0.98-1.11 1.06 0.99-1.13 1.16 1.11-1.22 1.17 1.11-1.22 
Race (reference: white) 1.33 0.84-2.12 1.87 1.00-3.48 1.24 0.86-1.79 1.08 0.97-1.21 
Family DM 1.15* 0.72-1.85   1.19** 0.82-1.72   
CD4++++ 1.02* 0.36-2.70   1.01** 0.36-1.00   
AIDS 1.24* 0.66-2.31   1.14** 0.69-1.88   
Lipoatrophy 1.03* 0.54-1.97   1.07** 0.64-1.78   
HAART 1.53* 0.64-3.68   1.37** 0.70-2.66   
 OR: odds ratio; AOR: adjusted odds ratio; BMI: Body mass index; HOMA-IR: homeostasis model assessment insulin resistance, CI: confidence interval 
 + per 20 unit decrease; ++ per 5 kg decrease, +++ per 5 year increase, ++++ per 100 unit increase 
 *Variable did not remain in the final diabetes multivariate model, **Variable did not remain in the final insulin resistance multivariate model.
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5.0  CONCLUSION 
In these studies, we used data from the Pitt Men’s Study and the Multicenter AIDS Cohort Study 
to investigate the associations of measures of physical function, as a correlate of physical 
activity, with diabetes mellitus and insulin resistance in both HIV-uninfected and HIV-infected 
men by addressing five aims.  This work is important because, to date, the published literature 
assessing the risk factors for glucose disorders in HIV-infected populations has not accounted for 
physical function or physical activity level, despite the known association in the general 
population.   
Our first goal was to investigate the role of self-reported low physical function as a risk 
factor for prevalent and incident diabetes mellitus among HIV-infected and HIV-uninfected men.  
Our results suggest that self-reported low physical function was associated with prevalent DM, 
independent of HIV status.  After adjustment for age and race, physical function remained 
significantly associated with DM prevalence such that for every 25 unit decrease in physical 
function score, the odds of having DM increased by 50% (p<0.05).  Similar findings were 
observed for incident diabetes; however stratification by HIV status and adjustment for 
covariates attenuated these results such that the physical function HR was reduced in HIV-
uninfected men (adjusted HR 1.23, 95% CI 0.94-1.23) and in HIV-infected men (unadjusted HR 
1.12, 95% CI 0.85-1.50)   Further, the choice of diabetes definition impacted our findings such 
that physical function was not associated with incident DM in HIV-infected men using a more 
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stringent definition, but was a significant risk factor when less stringent criteria were employed.  
This finding highlights the importance of careful consideration when choosing case definitions as 
well as the importance of proper interpretation of findings.   Interestingly, unlike previously 
published literature102-106, our research did not find a link between HAART use and incident 
diabetes among our study cohort, but instead found that, similar to the general population, the 
risks for diabetes included older age, non-white race, higher BMI and lower physical function 
level regardless of HAART use.  Our lack of an association with HAART is likely due to our use 
of HAART as a drug exposure class which may have reduced the effect of any individual 
medication or specific medication combinations. 
The second aim was to investigate the role of self-reported low physical function as a risk 
factor for prevalent and incident insulin resistance among HIV-infected and HIV-uninfected 
men; however results were contrary to our hypothesis.  Physical function was significantly 
associated with prevalent IR in univariate analysis in the Pitt Men’s Study Cohort; however it did 
not remain a significant risk factor after adjustment for covariates.  This result was replicated 
using MACS population.  Physical function was associated with IR among all men and among 
HIV-uninfected men in univariate, but not multivariate, analysis.  However, among HIV-infected 
men, physical function not significantly associated with IR even in univariate analysis.  The 
strength of the more traditional as well as HIV-specific risk factors in multivariate analysis may 
partially explain these findings.   
Our third aim was to compare incidence rates of diabetes in HIV-infected and HIV-
uninfected men with low physical function to rates in HIV-infected and HIV-uninfected men 
with high physical function.  Our results were consistent with the stated hypothesis.  The 
cumulative incidence of DM was highest among HIV-uninfected men with low physical function 
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and next highest in HIV-infected men with low physical function and lowest HIV-infected and 
uninfected men with high physical function, regardless of the stringency of the diabetes 
definition employed.  This finding is important because it shows that both HIV-infected and 
HIV-negative men with high physical function were more likely to remain diabetes free for a 
longer period of time.  Therefore, interventions aimed at increasing and maintaining high levels 
of physical function may reduce the number of new diabetes cases and limit the disabling effects 
of chronic diabetes. 
The goal of aim four was to assess the relationship between self-reported and 
performance-based measures of physical function in HIV-infected and HIV-uninfected men.  
Based on published literature in HIV-uninfected populations with chronic diseases222-228, we 
expected moderate correlations (ρ=0.25-0.5); however we found a slightly weaker correlation in 
our cohort for both HIV-uninfected (ρ=0.12-0.23) and HIV-infected men (ρ=0.16-0.24).  Our 
relatively heterogeneous sample of men may partially explain these findings.  In addition, 
comparisons with other studies are difficult due to the utilization of differing self-report 
questionnaires and performance-based measures from the comparison studies.  The relatively 
weak correlations reported in our study support the notion that psychosocial factors are important 
in self-reported physical function among HIV-infected individuals223 Therefore, it is likely that 
the most accurate measure of physical function in HIV-infected populations is a complementary 
approach that uses both self-report and performance-based measures. 
Finally, in aim five, our goal was to construct multivariate models to determine whether 
self-report or performance-based measures of physical function are more strongly associated 
with prevalent diabetes mellitus and insulin resistance in HIV-infected and HIV-uninfected men. 
Contrary to our hypothesis, we found that self-reported physical function, rather than the 
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performance-based measures, was more strongly associated with DM and IR.  The unadjusted 
OR was higher for self-report physical function compared with grip strength regardless of HIV 
serostatus.  This trend remained after adjustment for covariates.  Gait speed was not associated 
with diabetes or insulin resistance in either HIV-infected or uninfected men.  The perception of 
physical function compared with actual performance due to living with a chronic disease may 
partially explain these findings.  While the cross-sectional design of our study limited the 
directionality of our findings, the inclusion of both self-reported physical function and grip 
strength in the DM models supports the need for future prospective studies. 
5.1 FUTURE RESEARCH 
These studies suggest that low physical function, a correlate for low physical activity, is a risk 
factor for diabetes mellitus and insulin resistance in the Pitt Men’s Study and the Multicenter 
AIDS Cohort Study.  Given the strength of previous studies that support the strong correlation of 
physical function with physical activity in HIV-uninfected populations15-20, our results are 
consistent with the notion that low physical activity is a risk factor for incident DM in HIV-
uninfected and HIV-infected men. However, because the MACS never collected physical 
activity data, we were limited to the use of physical function.  The correlation between physical 
activity levels and physical function abilities in HIV-infected populations is currently unknown.  
Given the study population, we were also unable to assess these associations in HIV-infected 
women.  Therefore, important questions remain regarding the role of objectively measured 
physical activity as a risk factor for DM and IR in the general HIV-infected population.  Finally, 
the role of physical activity interventions in the prevention of DM in HIV-infected men and 
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women has yet to be addressed in large controlled trials. That is, do physical activity 
interventions prevent the development of DM in HIV-infected populations similar to the in 
general population?  In order to address these unanswered questions, future prospective studies 
and randomized controlled trials using objective physical activity measures and interventions are 
necessary.  Such studies should further explore: 1) the association between objectively measured 
levels of physical activity and actual physical function performance in HIV-infected populations; 
2) the role of objective measures of physical activity (i.e. using pedometer/accelerometer) with 
the onset of incident DM and IR in both HIV-infected men and HIV-infected women; 3) physical 
activity interventions, including exercise, to prevent DM among HIV-infected populations with 
normoglycemia and with those IGT.  These studies are essential in order to better understand the 
etiology and prevention of DM in HIV-infected populations. 
Further, the associations between performance-based measures of physical function, DM, 
and IR in this study were assessed in a cross-sectional analysis, thus the question of directionality 
between these associations remains unanswered.  A prospective study conducted in HIV-
uninfected individuals supports a relationship between grip strength and elevated fasting insulin 
levels, suggesting a biologically plausible link between lower muscular strength and the 
development of IR245.  However, the prospective association has yet to be studied in HIV-
infected populations.  Larger, prospective studies are necessary to determine whether or not 
performance-based measures of physical function can be used as markers of future IR and DM in 
HIV-infected cohorts.  This research is clinically important because identifying early functional 
markers of glucose disorders may help prevent further functional declines and chronic 
complications22, 25, especially among individuals with HIV-infection who may already be at risk 
for physical disability due to HIV associated symptoms220.    
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5.2 PUBLIC HEALTH RELEVANCE 
Type 2 diabetes mellitus and insulin resistance are prevalent and serious conditions among HIV-
uninfected and HIV-infected individuals.  These glucose disorders are a huge burden to the 
national health care system, costing an estimated $174 billion annually, with an additional $36.4 
billion required for new HIV infections7, 281.  Prior to the introduction of HAART, cases of 
diabetes mellitus and insulin resistance were rarely documented among HIV-infected 
individuals115.  Beginning as early as 1998, cross-sectional and cohort studies reported an 
increase in glucose disorders among HIV-infected individuals, often with higher prevalence rates 
than in their HIV-uninfected counterparts 14, 103, 108, 109, 114, 116-120.  This raised the spectra of an 
association between HIV, HAART, and diabetes mellitus.   However, a full understanding of 
these complications remains elusive, and likely involves a combination of antiretroviral therapy 
and duration of HIV infection (likely due to the pro-inflammatory effects of HIV itself103) as 
well as traditional risk factors such as lifestyle, body mass index (BMI)11, 107-110, age, sex, and 
genetic predisposition111, 112.   Given the burden of these diseases as well as the uncertainty 
regarding their cause, it has become essential to identify modifiable risk factors to help prevent 
the development of these glucose disorders, especially among individuals already living with 
chronic HIV infection. 
 Physical activity is one such risk factor.  Because physical activity and exercise are cost-
effective health promotion interventions that could decrease the need for health care resources, 
slow HIV disease progression, and prevent or delay the onset of chronic conditions, the role of 
physical activity as risk factor for diabetes in persons infected with HIV deserves attention.  
Unfortunately, it had been overlooked in the majority of studies of glucose disorders in HIV-
infected person, despite its acceptance as a known risk factor in the general population.  Thus, it 
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is important to recognize that the results of previous studies that observed an association between 
HAART use as well as other non-traditional risk factors, diabetes mellitus and insulin resistance 
might have been confounded by physical activity levels.   
The results of our work indicate that individuals with low self-reported physical function 
and grip strength, and thus likely low physical activity, have an increased risk of diabetes 
mellitus.  This trend, although present, was weaker among the HIV-infected men.  Regardless, 
the association deserves attention.  Given the known correlation between physical function and 
physical activity, it is biologically plausible to suggest that interventions aimed at increasing 
physical function and strength in HIV-infected populations will increase physical activity levels 
while reducing the incidence of DM.  However, it is also possible that the weaker association in 
HIV-infected men suggests that, at the very least, physical function and potentially physical 
activity interventions may not work as well to prevent DM in HIV-infected populations and that 
interventions deemed appropriate in the general population may not apply to all diseased 
subgroups.  Future studies that actually assess physical activity rather than physical function are 
essential in order to evaluate the effectiveness of physical activity as a modifiable risk factor for 
DM in HIV-infected populations. 
 In order to design appropriate interventions, it is essential to understand the entire 
physical function construct among individuals living with HIV.  Our work was the first to assess 
the relationship between self-report and performance-based measures of physical function in an 
HIV-infected cohort and demonstrated that both are essential to gain a full understanding of 
physical function in HIV-infected individuals.  The use of appropriately designed interventions 
could significantly reduce the number of incident diabetes cases in HIV-infected populations, 
while simultaneously decreasing the risk of further disability and chronic sequelae among HIV-
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infected individuals already diagnosed with diabetes.  This is of great public health significance 
given the national burden of both HIV infection and diabetes mellitus.   
Over the next decade, clinical trials among HIV-infected populations similar to those 
completed in HIV-uninfected populations are necessary in order to establish a casual association 
between low physical activity and the onset of DM and IR.  At present, researchers and clinicians 
alike are encouraged to consider the potential for a similar benefit to HIV-infected individuals as 
demonstrated in the general population.  As this relationship becomes more clearly recognized, 
increased physical activity will become an integral part of diabetes prevention and management 
in HIV-positive individuals.  Therefore, ongoing cohort studies addressing the issues of glucose 
metabolism in HIV-infected populations should address the role of physical activity and physical 
function in order to further clarify this relationship. 
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